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An impeding challenge to breast cancer drug therapies is the availability of more effective 
and less toxic chemotherapeutic agents that do not relay harm to neighboring normal breast 
cells and tissues.  Preliminary studies showed that the quinoline antimalarials, chloroquine 
(CQ) and hydroxychloroquine (HCQ), inhibit proliferation and induce differentiation in 
breast cancer cell lines without toxicity to normal MCF-10A breast cells.  Hence, the goal of 
these studies was to explore:  (1) whether a drug combination modulating epigenetic events 
would sensitize breast cancer cells to the antitumor activity of CQ or HCQ, (2) and if so, 
which would be the most promising combination of agents for the generation of safer and 
less toxic chemotherapeutic agents for the prevention and treatment of advanced breast 
cancer. We hypothesized that the use of a drug combination modulating epigenetic events 
would lower the concentration of CQ or HCQ needed to produce the differentiation 
response.  Hence, the quinoline agents were used in combination with the demethylating 
agent, 5-Aza-2’-deoxycytidine (5-Aza-dC or Aza), or with the differentiating agent, all-
trans-Retinoic acid (ATRA) in order to lower the threshold for chemotherapy-induced cell 
death in breast cancer cells.  Cell survival, cellular differentiation, and histone H3/H4 
acetylation status were measured to show that combination of 5-Aza-dC or ATRA with the 
quinolines sensitized breast cancer cells to enhanced growth inhibition, differentiation, and 
histone hyperacetylation compared to cells treated with either CQ or HCQ alone.  
Furthermore, ATRA was identified as a direct HDAC inhibitor and upon combination 
treatment with HCQ had the most significant inhibitory effect on tumor cell clonogenic 
survival in both estrogen receptor (ER+) and (ER-) breast cancers.  Thus, ATRA combined 
with HCQ served as the most promising combination of chemotherapeutic agents and were 
subsequently assessed using a new and highly sensitive assay for histone acetylation by 
mass spectrometry to generate a profile on lysine modification (acetylation/deacetylation).  
The combination of ATRA with HCQ increased acetylation of N-terminal lysine residues on 
histones H3/H4 as well as caused direct HAT activation.  The overall data suggest that HCQ 
might contribute to breast cancer cell differentiation by modulating HAT activity; whereas, 
ATRA sensitizes breast cancer cells to the antitumor activity of HCQ via regulation of both 
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1.  Breast Cancer 
 Breast cancer affects many individuals around the world.  For this year, 2004, it is 
estimated that 215,990 new cases of invasive breast cancer will be diagnosed among women 
in the United States alone.  Breast cancer affects men as well and is estimated that 1,450 
new cases of breast cancer will arise among men.  Breast cancer is the most frequently 
diagnosed cancer among women and the second leading cause of cancer related deaths, after 
lung cancer.  An estimated 40,580 deaths are anticipated in 2004 (American Cancer Society, 
2004).  Breast cancer is a cellular disease, which is the outcome of aberrant cell growth 
starting in the breast tissue.  From the breast tissue, malignant tumors are able to metastasize 
to other organs of the body, making breast cancer so deadly.  There have been insights into 
the causes of breast cancer and a myriad of epidemiological studies that provide a 
correlation between environmental, racial, and cultural influences and the occurrence of 
cancerous cells; however, both the absolute cause of breast cancer and the means for its cure 
still remain unknown (Polyak, 2001). 
 
1.1  Oncogenes and Tumor Suppressors 
 Two gene classes play a pertinent role in the development of cancer:  proto-
oncogenes and tumor suppressor genes.  Proto-oncogenes encourage growth and code for 
proteins that stimulate cell division.  On the other hand, tumor suppressor genes, which are 
known as the “guardians of the genome” code for proteins that inhibit cell division 
(Weinberg, 1996).  Since collaboration between cells ensures that the size as well as the 
structure of the breast tissue is maintained, normal cells reproduce only when instructed to 
do so by other cells in their vicinity.  To the contrary, cancer cells violate this scheme and 
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overexpress stimulatory proteins that regulate the cell cycle.  When a proto-oncogene 
becomes mutated, it is called an oncogene, and can cause overexpression of these 
stimulatory proteins.  Some genes that function as oncogenes in breast cancer include c-myc, 
erb-B2 (HER-2 or neu), Bcl-2, Bcl-1, and Mdm2.  Mutations in tumor suppressor genes can 
cause the proteins that inhibit cell division to be inactivated; therefore, depriving cells of 
essential restraints on proliferation.  Some genes that function as tumor suppressor genes in 
the breast include Rb, p53, BRCA1, and BRCA2 (Kopnin, 2000).  
The human epidermal growth factor receptor 2 gene encodes HER-2/neu, which is an 
epithelial cell surface receptor that expresses tyrosine kinase activity.  In normal cells, HER-
2/neu acts as a receptor for cellular growth factors, thereby, regulating cell growth and 
division.  However, in cancer cells HER-2/neu acts as an oncogene and loses its normal 
response to regulatory proteins, thus resulting in unregulated progression of cell growth.  
About 25-30% of patients with invasive breast cancer overexpress HER-2/neu, which has 
been shown to play an important role in the malignant transformation and aggressiveness of 
breast cancer. It is also associated with early recurrence, shorter disease-free interval, and 
overall poorer outcome in breast cancer (de Bono et al., 2003).          
There is a significant correlation between breast cancer and the inherited form of the 
disease.  Breast cancer susceptibility genes, BRCA1 and BRCA2 account for 83% of breast 
cancers occurring by age 70.  However, only about 20% of women with familial history of 
breast cancer carry these inherited genes, indicating that the majority of breast cancers do 
not develop solely because of heredity (Prichard et al., 2003).  Mutations in the DNA of a 
normal cell account for the development of the majority of breast cancer, thus making the 
offspring more susceptible to cancer.  BRCA1 and BRCA2 instruct large proteins involved 
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in the transition from S to G2 phase of the cell cycle.  They play a pertinent role in the 
maintenance of chromatin structure by aiding in DNA strand break repair.  When cells enter 
G2 arrest, they are held there and repaired by either BRCA1 or BRCA2; therefore, 
mutations in these genes result in the lack of or incorrect repair of DNA (Kopnin, 2000). 
The failure of DNA damage to be corrected in cellular reproduction is one of the main 
reasons for cancer.  The tumor suppressor gene, p53, can correct DNA damage, and 
subsequently prevent aberrant cell growth.  Sequences at the N-terminus of the p53 protein 
function as transcriptional activators, which activate the transcription of genes involved in 
the suppression of cell growth (Hanahan and Weinberg, 2000). 
 
1.2  Cell Cycle 
The cell cycle consists of four stages:  G1, S, G2, and M phase.  During the longest 
phase, G1 (gap 1), the cell increases in size and prepares to replicate its DNA.  The 
replication occurs in the next phase, S (for synthesis), but before the cell proceeds to the 
next phase it must make a transition that occurs at the restriction point (R) in G1, which 
commits the cell to the proliferative cycle.  If the conditions that signal this transition are not 
present, the cell exits the cell cycle and enters G0, a nonproliferative phase during which 
growth, differentiation and apoptosis occur.  Once the cell has passed the restriction point, it 
is ready to enter the S phase, which allows for the duplication of the precise complement of 
chromosomes.  A second gap phase, G2, follows after replication and allows for the cell to 
prepare for the final phase, M (mitosis).  During M phase, the parent cell divides in half to 
generate two daughter cells, each of which is endowed with a complete set of chromosomes.  
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The new daughter cells may then enter G1 and proceed through the full cycle again, or they 
may stop cycling temporarily or permanently in the G0 resting phase (Weinberg, 1996).   
Passage through the four phases of the cell cycle is regulated by a family of cyclins that 
act as regulatory subunits for cyclin-dependent kinases (cdks). The activity of the various 
cyclin/cdk complexes that regulate the progression through G1, S, and G2 phases of the cell 
cycle is controlled by the synthesis of the appropriate cyclins during a specific phase of the 
cell cycle.  Each cyclin binds to the corresponding cdk and activates its catalytic subunit 
with sequential phosphorylation and dephosphorylation of key residues.  In early G1, a 
cyclin cdk complex is formed with either cdk4 or cdk6 bound to a cyclin D isoform.  Several 
proteins can inhibit the cell cycle in the G1 phase (Figure 1). If DNA damage has occurred, 
p53 accumulates in the cell and induces the p21-mediated inhibition of cyclin D/cdk4/6.  
Mdm2, which is responsible for the inactivation and nuclear export of p53, becomes part of 
an inhibitory feedback loop that inactivates p21-mediated G1 arrest. Similarly, activation of 
TGF-β receptors induces the inhibition of cyclin D/cdk by p15, while cyclic AMP inhibits 
the cyclin D/cdk complex via p27. If the cyclin D/cdk complex is inhibited, retinoblastoma 
protein (Rb) is in a state of low phosphorylation and is tightly bound to the transcription 
factor E2F, inhibiting its activity and therefore, inhibiting cell cycle progression. 
Passage through the restriction point and transition to S phase is triggered by the 
activation of the cyclin D/cdk4/6 complex, which phosphorylates Rb. Phosphorylated Rb 
dissociates from E2F, which is then free to initiate DNA replication. Cyclin E/cdk2 
accumulates during late G phase and triggers the passage into S phase. The synthesis and 
accumulation of cyclin B/cdk2 also begins during S phase, but the complex is 
phosphorylated at Thr14 -Tyr15 and remains inactive. Cyclin A/cdk2 accumulates during S 
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phase and its activation triggers the transition to G2, a phase characterized by the 
accumulation of cyclin B/cdk2, DNA replication, cell growth and new protein synthesis 
(Weinberg, 1996; Hanahan and Weinberg, 2000). 
Mutations and abnormalities in the regulatory cell cycle proteins are frequent in most 
cancer types.  Normal cells reproduce only when instructed to do so and are subject to strict 
control of cell cycle regulation.  On the other hand, cancer cells have their own internal 

























































1.3  Methods of Treatment 
Current methods of treatment include local and systemic treatment.  Local treatment 
includes lumpectomy, mastectomy, or radiation therapy.  Systemic treatment involves 
hormone therapy or chemotherapy, depending on whether the breast cancer is estrogen 
receptor (ER+) and progesterone receptor (PR+). 
 
1.3.1  Local Treatment     
Breast-conserving surgery involves lumpectomy, or the surgical removal of a tumor and 
the surrounding clean margin of normal tissue, followed by radiation therapy.  The goal of 
this treatment is to excise the tumor, while maintaining a cosmetically acceptable breast.  It 
has proven to be effective for early-stage breast cancers that have not metastasized or spread 
to other organs in the body.    
Mastectomy, or the surgical removal of the breast, can be accomplished in several 
different ways depending on the size of the tumor and the extent of the disease. Either the 
entire breast and lymph nodes are removed or just the breast is removed, leaving the lymph 
nodes intact (Sakorafas, 2000).  Because mastectomy requires more extensive surgery than 
does a lumpectomy, greater discomfort occurs.  
Radiation therapy, which includes the use of high-energy waves (x-rays or gamma rays) 
or streams of particles (electrons, protons, neutrons, alpha particles, and beta particles), 
works by damaging DNA.  It is estimated that 50-60% of all patients with cancer will 
receive radiation at some time during their cancer treatment.   Radiation therapy is more 
successful on cells that are actively reproducing and on those that divide more rapidly 
(Sullivan, 1980). It is less effective on cells that are in the resting phase or that divide 
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slowly.  Although radiation therapy attacks reproducing cells, it does not display selectivity 
and therefore, does not distinguish between cancer cells and cells of normal tissues. The 
damage to normal cells can result in side effects.  A balance between eradicating the cancer 
cells and sparing the normal cells, in order to minimize undesirable side effects is involved 
each time radiation therapy is given.   For this reason, radiation treatment is given in small 
doses or fractions over several weeks to allow the optimal dose to kill the cancer with less 
damage to normal tissues. 
Radiation therapy is used as an adjuvant treatment in addition to the primary treatment, 
which is usually surgery.  It is used before surgery to shrink a large tumor so that the tumor 
can be surgically removed and to relieve symptoms such as pain and bleeding when the 
cancer has spread.  It is given about one month after a lumpectomy or mastectomy to destroy 
malignant cells that may remain undetected in the breast region, which includes the breast, 
chest wall, or armpit. 
 
1.3.2  Systemic Treatment     
Hormone therapy, which is also known as endocrine therapy, is used for hormone 
dependent breast cancer.  Estrogen and progesterone hormones circulate in the bloodstream 
and can attach to breast cancer cells, and thereby, support the growth of the cancer.  
Estrogen is the major promoter of cell growth in hormone dependent breast cancer. The goal 
of hormone therapy is to deprive the cancer tissue of estrogen, resulting in the blocking or 
slowing of cancer cell growth. Unlike chemotherapy, hormone therapy does not kill the 
cancer cell. Hormone therapy acts by either blocking estrogen from reaching cancer cells, 
receptor blocker, or inhibiting the synthesis of estrogen. The specific hormone treatment 
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chosen depends on many factors including whether the tumor is estrogen and/or 
progesterone receptor positive or negative.  Hormone therapy is effective only in hormone 
receptor-positive or unknown status breast cancers. Hormone therapy is not used with 
ER/PR negative breast cancers, as they are unlikely to respond to hormone therapy.  
Hormone treatments include estrogen receptor modulators, aromatase inhibitors, or 
progestins. (Osborne et al., 2000) 
Estrogen receptor modulators block estrogen's action at the tumor.  The oldest and most 
commonly used antiestrogen drug is tamoxifen, which is an effective treatment for both 
early and advanced stage breast cancer. Tamoxifen, which is used as a first-line hormone 
therapy, does not stop estrogen from being made in the body, but it prevents breast cancer 
cells from growing by blocking the estrogen receptors in the cancer cells and thereby, 
preventing the estrogen hormone from reaching the receptor (Osborne et al., 2000).   
Although there are some serious side effects to tamoxifen treatment, in most cases they are 
outweighed by the benefits of the drug on breast cancer.  Randomized trials have failed to 
demonstrate an advantage for taking tamoxifen for more than five years, so the current 
practice is to take the drug for five years only.  However, tamoxifen is the most frequently 
prescribed cancer drug worldwide, and the only antiestrogen approved to lower the risk of 
breast cancer in high-risk women.  Another antiestrogen, osteoporosis-preventing drug, 
raloxifene, is currently being studied in a large number of healthy, high-risk women 
throughout the country to determine how its cancer-prevention benefits compare with 
tamoxifen (Prichard et al., 2003).  
Aromatase inhibitors, such as anastrozole, letrozole, and exemestane are used as second-
line hormone therapy.  These drugs work by blocking a specific enzyme necessary for 
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estrogen production in the fat tissues, including the breast, of postmenopausal women. These 
estrogen reducing drugs are used in advanced or metastatic breast cancer as first-line therapy 
or second-line therapy after tamoxifen. (Osborne et al., 2000) 
Progestins, which are progesterone like drugs such as megestrol acetate, reduce the effect 
of estrogen on breast cancer cells.  They are traditionally used in postmenopausal women as 
a third-line therapy after tamoxifen and the aromatase inhibitors. 
 Chemotherapy is the systemic use of natural or synthetic chemical agents utilized in 
order to reverse or suppress the progression to an invasive carcinoma (Prichard et al., 2003).  
It is considered a systemic therapy since it enters the bloodstream and is distributed 
throughout the body, except for the brain, so that it can damage or destroy cancer cells.  
Studies have shown that the combinations of chemotherapy drugs are the most efficacious, 
by offering distinct ways of destroying the cancer cells; thereby, reducing the chance of the 
cancer becoming resistant to one drug.  Some of the drugs used in combination are 
cyclophosphamide, methotrexate, and 5-fluorouracil, with or without prednisone, or 
vincristine, as well as doxorubicin with paclitaxel.  The drug combinations are usually either 
DNA alkylating agents, mitotic spindle inhibitors, antimetabolites, or DNA intercalators. 
Chemotherapy destroys proliferating cells and does not distinguish between cancer cells 
and normal, healthy cells. When normal cells are killed, side effects from the drugs occur. 
Because cells of the skin, nails, and hair divide quickly, chemotherapy causes hair thinning 
or loss of hair over the entire body, dry skin, and weak nails.  Chemotherapy drugs are 
immunosuppressive and interfere with blood cell production.  Chemotherapy drugs may also 
induce early or premature menopause, particularly in older women. Some drugs, such as 
doxorubicin or epirubilin can cause permanent damage to the heart; therefore, measures 
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have to be taken to limit the amount of drug that is used and to monitor heart function 
periodically during therapy. More rarely, certain drugs may cause another cancer to develop 
as a result of the chemotherapy itself, such as leukemia.   
Another method of systemic treatment includes immunotherapy, which enhances the 
body's own defense system, enabling it to destroy cancer cells. While different 
immunotherapy approaches, such as anti-tumor vaccines, are under investigation for breast 
cancer, thus far none have been shown to work for breast cancer.   Trastuzumab (Herceptin) 
is a monoclonal antibody that binds with HER-2/neu receptors on the surface of some breast 
cancers (Prichard et al., 2003).  The proto-oncogene, HER-2/neu (or erbB2), is a gene that 
occurs normally in our bodies.  However, during the evolution from normal to cancer cells, 
this gene often mutates and becomes an oncogene. When it does so, it generates excessive 
amounts of growth promoting proteins called growth factors.  When the HER-2/neu protein 
binds to the receptor on the tumor cell surface, the MAPK (mitogen-activated protein 
kinase) signaling pathway is activated causing the cell to divide.  Herceptin binds to the 
HER-2/neu receptor, making it impossible for the growth promoting protein to bind and 
therefore, inhibits the tumor from growing (de Bono et al., 2003).  When used in 
combination with other chemotherapy drugs such as paclitaxel, doxorubicin, and 
cyclophosphamide, it increases the potential of these drugs so that they are more effective in 
tumors than the drugs alone.  Herceptin alone is for patients whose tumors have progressed 
in spite of standard chemotherapy regimens.  A serious side effect for this drug is heart 
toxicity, which is more common among those who take Herceptin in combination with 
anthracyclines, such as doxorubicin and epirubicin.  
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As can be seen from the above chemoprevention agents, a pertinent challenge to breast 
cancer drug therapies is the availability of more promising antitumor agents that have the 
ability to eradicate breast tumor cells without displaying toxicity to neighboring normal 
breast cells and tissues.  Despite improvements in therapeutic treatments for breast cancer 
within the last thirty years, there is still a lack of effective chemoprevention agents that are 
active against breast cancer and that do not display harmful toxicity at higher doses.  Novel 
strategies must be devised to administer potent therapy against cancer cells without the side 













2.  Quinolines 
Chloroquine and hydroxychloroquine belong to the quinolone family and possess diverse 
pharmacological properties including antimalarial and anti-inflammatory activity, which are 
exploited clinically.  They are related drugs with different therapeutic and clinical 
indications for use.  Initially, both chloroquine and hydroxychloroquine were given for 
malaria prophylaxis and treatment, and, later, they were used by rheumatologists for treating 
rheumatoid arthritis, systemic/discoid lupus erythematosus, and other connective tissue 
disorders (Scheibal and Van Dyke, 1997).  Currently, chloroquine is used as an antimalarial 
and hydroxychloroquine is used to treat rheumatoid arthritis.   
 
2.1  Chloroquine (CQ) 
Chloroquine (Aralen) is a 4-aminoquinoline compound (figure 2) that displays 
antimalarial activity.  Chloroquine is an effective antimalarial drug, especially against the 
asexual intraerythrocytic forms of human plasmodia, because it is concentrated in the 
erythrocyte of the malarial parasite (Parris, 2003).  The quinoline drug has been proposed to 
selectively target the parasite by inhibition of parasite feeding of hemoglobin.  Chloroquine 
is an effective inhibitor of catalase activity of heme.  The catalase activity converts hydrogen 
peroxide to water and oxygen; thereby, detoxifying the reactive oxygen species.  Inhibition 
of this process by chloroquine, therefore, makes the heme toxic to the parasite (Foley and 
Tilley, 1998).  Chloroquine can also exert its actions by intercalating into DNA and binding 
to ferriprotoporphyrin IX in the phagocytic vesicles of the parasite (Misra et al., 1997).  
Chloroquine is also an effective anti-inflammatory agent that has been shown to reduce 
proinflammatory cytokine release in both in vitro and in vivo studies.  Chloroquine blocks 
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interleukin-mediated induction of NF-κB, a nuclear transcription factor primarily 
responsible for induction of key inflammatory proteins involved in inflammation (Bonizzi et 
al.,1997).  Chloroquiine also inhibits the production of TNF, a potent immunoregulatory 
cytokine which is associated with inflammatory diseases such as rheumatoid arthritis, 
multiple sclerosis, and cerebral malaria (Jeong et al., 1997; Hong et al., 2004).   
Interestingly, chloroquine also displays antitumor activity.  In cultured mouse myeloid 
leukemia cells, chloroquine induced differentiation and inhibited DNA and RNA 
polymerases (Morrow et al., 1989).   Preliminary results also showed that chloroquine 
caused cell differentiation in a panel of beast cancer cells while having no effect on normal 
mammary epithelial cells.  Chloroquine may be a promising candidate for breast cancer 
treatment.  The advantage of using this quinoline for breast cancer treatment is that is in 
wide use and its human pharmacology is well known (Scheibal and Van Dyke, 1997).    
Although, at an extremely high dose (>100 g/ml), chloroquine can generate ocular toxicity, 
it displays very low and predictable toxicities in humans (Foley and Tilley, 1998).   
Combination therapy of other differentiating agents with chloroquine may be a promising 
option for breast cancer treatment by permitting lower doses of chloroquine for maximum 
therapeutic effects. 
 
2.2  Hydroxychloroquine (HCQ) 
Hydroxychloroquine (Plaquenil) is a 4-aminoquinoline compound (figure 2) that also 
displays antimalarial activity.  Most notably, hydroxychloroquine is already widely used by 
many pre- and post-menopausal women to treat rheumatoid arthritis because of its efficacy 
and low toxicity profile (Suarez-Almazor et al., 2000).  Hydroxychloroquine also inhibits 
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induction of TNF and NF-κB production necessary for inflammation (Jeong et al., 1997).  
Long term use of the quinoline, hydroxychloroquine has shown that it is relatively safe and 
affords other benefits.  It may be used in pregnancy, has steroid sparing effects, and 
alleviates the risk of thrombosis associated with antiphospholipid antibodies.  When used for 
the treatment of mild to moderate lupus, hydroxychloroquine lowered serum levels of 
cholesterol, triglycerides, and LDL in patients (Cruz, 2001).  In lupus patients, treatment 
with hydroxychloroquine also decreased mean blood glucose levels (Petri, 1996). 
Preliminary results also showed that hydroxychloroquine caused cell differentiation in 
MCF-7 and MDA-MB-231 beast cancer cells while having no effect on normal mammary 
epithelial cells.  Hydroxychloroquine may be a promising candidate for breast cancer 
treatment, especially because of its many advantages and its low toxicity profile.  Another 
advantage of using this quinoline for breast cancer treatment is that is already widely used 
and its human pharmacology is well known (Scheibal and Van Dyke, 1997).    Combination 
therapy of other differentiating agents with hydroxychloroquine may be a promising option 
for breast cancer treatment by possibly enhancing its therapeutic effects. 



























3.  Histone Acetylation Status and Breast Cancer 
Organization of chromatin structure is a fundamental component of transcriptional 
regulation (Hanahan et al., 2000).  Modifications of histones, the building blocks of 
chromatin, serve as significant determinants in the eventual fate of all eukaryotic cells.  
Post-tanslational modifications of histones include methylation, phosphorylation, and 
acetylation; however, acetylation is the best understood of these modifications 
(Khorasanizadeh, 2004).  Much evidence suggests that changes in acetylation or 
deacetylation of nucleosome core histones play a role in the uncontrolled growth and 
development of cancer (Yoshida et al., 1999; Zhou et al., 2000; Walia et al., 1998).  The 
acetylation status of histones is critical in the modulation of chromatin structure and the 
regulation of gene transcription.  Alteration of chromatin structure via histone acetylation, 
has long been associated with transcriptional activation (Hebbes et al., 1988), whereas 
deacetylation of histones has been associated with gene silencing and transcriptional 
repression (Vigushin et al., 2002). 
 
3.1  Chromatin Regulation 
 The activities of two families of enzymes, the histone acetyl transferases (HATs) and 
histone deacetylases (HDACs), control the acetylation status of histones.  Whereas HAT 
acetylates the nucleosome core histones, HDAC is responsible for the removal of acetyl 
groups from lysine residues in these histones (Walia et al., 1998).  The principal targets for 
this acetylation or deacetylation are at the N-terminal tail domains of lysine residues on 
histone H3 or histone H4 (Figure 3).  When HDAC deacetylates histone H3 or histone H4 at 
their respective lysine sites, the positively charged lysine residues on the hypoacetylated 
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histone bind tightly to the negatively charged phosphate backbone of DNA; thereby, 
maintaining chromatin in a transcriptionally silent state by preventing access of transcription 
factors, transcriptional regulatory complexes, and RNA polymerases to DNA (Yoshida et 
al., 1999).  The active site in the catalytic domain of HDAC consists of a curved tubular 
pocket.  A charge-relay system is used in order to remove an acetyl group.  An essential 
component of this charge-relay system is the presence of a zinc ion, which is bound to the 
zinc binding site on the bottom of the pocket (de Ruijter et al., 2003).  Since HDAC 
condenses chromatin into a tightly supercoiled conformation characteristic of 
transcriptionally inactive or repressed genes, it is thought to be a critical player in triggering 
cell growth and ultimately tumor progression (Vigushin et al., 2002); therefore, inhibition of 
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Figure 3. Schematic representation of nucleosome core histones.  Pink color represents 
histones in the core octamer.  The N-terminal histone tail of histones H3/H4 can be 
acetylated by the histone acetyltransferase (HAT) enzyme.  A red circle depicts an N-
terminal tail that has been deacetylated.  DNA is shown in black wrapped around the 







3.2  Pharmacological HDAC Inhibitors 
 There are many histone deacetylase (HDAC) inhibitors known, but the most potent 
discovered so far is trichostatin A (TSA).  TSA inhibits HDAC by displacing the zinc ion in 
HDAC’s active site and therefore, rendering the charge-relay system dysfunctional.  
Originally, TSA was used as an antifungal agent; however, later it was discovered to have 
significant antiproliferative activity in cancerous cells.  It belongs to the hydroxamic acid 
family of compounds and is effective at nanomolar concentrations in vivo.  Due to the 
extremely high cost, inefficient production, and toxicity of TSA, the search for alternative 
HDAC inhibitors has been ongoing and of great importance (de Ruijter et al., 2003). 
 Another renowned group of HDAC inhibitors include short-chain fatty acids, such as 
sodium butyrate, phenylbutyrate, and valproic acid; however, these compounds are less 
efficient in their HDAC inhibitory activity than TSA. 
 Cyclic tetrapeptide antibiotics are the third group of HDAC inhibitors and include: 
trapoxin, depsipeptide, apicidine, depudesin, chlamydocin, and HC-toxin.  Most of these 
compounds are products of bacteria or fungi.  Apicidine and depsipeptide are composed of  
a combination of hydroxamic acids and cyclic tetrapeptides. 
 All of these HDAC inhibitors work by inhibiting HDAC in a reversible fashion.  
Trapoxin and depudesin are exceptions and instead they irreversibly inhibit HDAC via 






4.  Retinoids and Breast Cancer 
 Vitamin A plays a critical role in epithelial cell differentiation.  Since 
undifferentiated cells are more susceptible to insults and neoplastic changes, vitamin A has 
been studied as a chemoprevention agent and a treatment modality for breast cancer.  
Vitamin A must be obtained from the diet as either preformed vitamin A (mainly as retinol 
or retinyl ester) or as provitamin A carotenoids that are converted to vitamin A within the 
body (Paik et al., 2003).  Chemically synthesized compounds that mimic biological actions 
of vitamin A are collectively known as retinoids.  These vitamin A derivatives, which 
include retinol, retinal, and retinoic acid are vital for normal growth, vision, tissue 
maintenance, reproduction, and overall survival (Chambon, 1994).  At the molecular level, 
retinoids play a myriad of potential roles in the prevention or repression of breast cancer 
cells, including growth inhibition, cell differentiation, and induction of apoptosis.  
Clinically, retinoids are able to reverse premalignant lesions and inhibit the generation of 
second primary tumors in some patients (Yang et al., 2002).  
 
4.1  Retinoid Metabolism  
 Intestinal absorption of vitamin A is necessary for survival.  Two sources of vitamin 
A are available:  carotenoids from fruits and vegetables as well as retinyl esters from animal 
tissues (Demmer et al., 1987).  β-Carotene, or provitamin A, which is one of the more 
prevalent biologically active carotenoids, undergoes cleavage by a soluble dioxygenase 
located in the small intestinal mucosa resulting in two molecules of retinal.  These 
molecules are subsequently reduced to retinol by retinaldehyde reductase.  Within the gut 
lumen, dietary retinyl esters are converted to retinol and subsequently taken up by the small 
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intestinal lining cell or enterocyte, where retinol gets esterified to retinyl palmitate.  The 
resulting retinyl esters are then incorporated into the core of chylomicron particles before 
they are exported from the small intestine and delivered to the blood.  Finally, the principal 
site of storage of vitamin A is the liver, where the retinol formed is stored as retinyl esters. 
At least four important intracellular binding proteins are thought to participate in the 
uptake and intracellular metabolism of vitamin A:  cellular retinol binding proteins (CRBPs) 
I and II (Demmer et al., 1987; Yang et al., 2002) and cellular retinoic acid binding proteins 
(CRABPs) I and II (Napoli, 1999).  All vertebrates express each of these high-affinity, 
highly conserved cytoplasmic proteins.  CRBPs I and II selectively bind retinal and retinol 
and discriminate against retinoic acid, whereas CRABPs I and II selectively bind retinoic 
acid and discriminate against retinal and retinol; thus, these intracellular binding proteins 
regulate the level of retinoic acid available for interaction with nuclear receptors.  Increasing 
data suggest that these proteins play a very pertinent role in the intestinal absorption and 
regulation of retinoid metabolism.  Defective expression of the cytoplasmic CRBPs can alter 
retinoic acid availability and lead to aberrant retinoid signaling, which has been reported in 
human breast cancer cell lines (Jing et al., 1996) and tumors (Kuppumbatti et al., 2000).  
 
4.2  Retinoid Signaling 
 Two types of nuclear retinoid receptor transduce the retinoid signals:  retinoic acid 
receptors (RARs) and retinoid X receptors (RXRs), which are members of the 
steroid/thyroid hormone receptor superfamily.  Both types of receptor are comprised of three 
distinct genes designated α, β, and γ.  In turn, each gene occurs as multiple isoforms 
(denoted by numerals) that may be generated through the utilization of alternative 
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transcription promoters, mRNA splicing, and the usage of more than one translation 
initiation codon (Lefebvre, 2001; Paik et al., 2003).  Interestingly, RXRs are heterodimeric 
partners not only for RARs, but also for other nuclear receptors such as thyroid hormone 
receptors, vitamin D receptor, peroxisome proliferator activated receptors, and a number of 
orphan nuclear receptors (Lefebvre, 2001).  The RXR-RAR heterodimers, as well as RXR-
RXR homodimers, function as ligand dependent transcription factors that regulate 
transcription by binding to specific retinoic acid response elements (RAREs) located in the 
5′-upstream region of target genes (Paik et al., 2003).  The naturally occurring retinoids 
known to transactivate RARs and RXRs are all-trans-retinoic acid (ATRA) and 9-cis-
retinoic acid, respectively (Figure 4).  These retinoic acid isomers are available at low levels 
in tissues; however, most tissues express oxidative enzymes that are able to activate vitamin 
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4.3  Retinoid Agents 
 All-trans-retinoic acid has been studied extensively in clinical trials.  The biological 
activity of all-trans-retinoic acid (ATRA) was assessed when used in combination with 
tamoxifen.  ATRA alone caused a 33% induction of RARβ in patients.  Combination 
therapy with tamoxifen potentiated the ATRA-induced biological changes (Toma et al., 
2000).     
The most widely studied retinoid in chemoprevention clinical trials is fenretinide (N-(4-
hydroxyphenyl)retinamide), which is a synthetic derivative of ATRA.  Experiments 
assessing the biological activity of fenretinide showed that the drug displayed preferential 
accumulation in the breast instead of the liver (Sporn et al., 1976).   Fenretinide has shown 
low toxicity and antiproliferative activity in mammary carcinomas (Mehta et al., 1991).  
Although, the parent compound, ATRA, is well known for its differentiating activity, 
fenretinide instead inhibits cell growth through the induction of apoptosis.  Although the 
mechanism is not well understood, it is thought to work by upregulating RARβ, TGFβ, or 










5.  Methylation Status and Breast Cancer 
 Not only is the degree of core histone acetylation important in modulating 
transcriptional regulation, but DNA methylation status serves as a critical determinant of 
chromatin structure and function as well (Fabian and Kimler, 2001; Wang et al, 2001).  In 
general, DNA methylation induces hypoacetylation of histones on heterochromatin, and thus 
leads to transcriptional repression (El-Osta et al., 2002; Hu et al., 2000).  For this reason, 
DNA methylation is often associated with the pathological silencing of tumor suppressor 
genes in human cancers (Ferguson et al., 1997; Yang et al., 2001).  The mechanisms linking 
DNA methylation and histone deacetylation in the control of gene expression have been 
established.  Recent studies have demonstrated that inhibitory transcription factors recruit 
DNA methyltransferase-1 (DNMT1) to chromatin, which subsequently methylates the CG 
dinucleotide in the promoter region of target genes.  The transcriptional repressor methyl-
cytosine binding protein 2 (MeCP2) then binds to the methylated CG dinucleotides and 
interacts in a complex with HDAC and the corepressor mSin3 to alter chromatin architecture 
and gene regulation (Hu et al., 2000).  It has been shown that DNMT also interacts directly 
with HDAC to generate a transcriptionally inactive chromatin structure (Spencer and Davie, 
2000; Yang et al., 2001).  The formation of MeCP2/mSin3/HDAC and DNMT1/HDAC 
transcriptional repression complexes are emerging as an important mechanism in silencing a 
variety of genes in breast cancer.  Compounds used to reverse the methylation of chromatin 





5.1  5-Aza-2’-deoxycytidine 
The cytosine analog 5-Aza-2’-deoxycytidine (5-Aza-dC) is a potent inhibitor of DNMT.  
5-Aza-dC has showed clinical utility and success in the treatment of human blood diseases 
and tumor progression, which in large part is attributed to its ability to induce cellular 
differentiation as a result of hypomethylation (Ferguson et al., 1997).  Other studies have 
showed that 5-Aza-dC treatment on estrogen receptor (ER)-negative human breast cancer 
cells, which have a hypermethylated ER gene promoter, led to reexpression of the ER gene 
and apoptosis of the cancer cells (Ferguson et al., 1997; Yang et al., 2001; Worm et al., 
2001).  When 5-Aza-dC treatment was combined with the HDAC inhibitor, trichostatin A 
(TSA), there was a 10-fold greater elevation in ER mRNA levels, suggesting that the 
combination of a DNMT1 inhibitor with HDAC inhibitors may play a pertinent therapeutic 
role in the management of (ER)-negative breast cancers (Yang et al., 2001).  Other reports 
have also demonstrated that the antitumor activity of HDAC inhibitors with 5-Aza-dC is 
synergistic in a panel of human cancer cell lines, suggesting a correlative link between the 
antiproliferative and pro-apoptotic activities of the DNMT1 inhibitor, 5-Aza-dC, and HDAC 









6.  Research Objectives 
Preliminary studies showed that two of the quinoline antimalarials, chloroquine (CQ) and 
hydroxychloroquine (HCQ), displayed selective toxicity only to breast cancer cells.  Hence 
the goal of these studies was to explore:  (1) whether a drug combination modulating 
epigenetic events would sensitize breast cancer cells to the antitumor activity of CQ or 
HCQ, (2) and if so, which would be the most promising combination of agents for the 
generation of safer and less toxic chemotherapeutic agents for the prevention and treatment 
of advanced breast cancer.  
 
1.  Hypothesis 1:  Combination of epigenetic agents will augment the antiproliferative 
effects of CQ and/or HCQ (Model 1).  MCF-7, estrogen receptor (ER+), and MDA-MB-
231 (ER-) transformed human breast cancer cell lines were used in comparison with MCF-
10A non-transformed immortalized human epithelial cell line.  All-trans-retinoic acid 
(ATRA) or 5-Aza-2’-deoxycytidine (5-Aza-dC; Aza) was combined with either CQ or 
HCQ.  Cell survival was measured using three endpoints: 
 (1)  MTS metabolism assay 
 (2)  cell growth curve 
 (3)  clonogenic survival 
  
2.  Hypothesis 2:  Combination of epigenetic agents will augment the differentiation 
response to CQ and/or HCQ (Model 1).  MCF-7, estrogen receptor (ER+), and MDA-MB-
231 (ER-) transformed human breast cancer cell lines were used.  ATRA or 5-Aza-dC (Aza) 
was combined with either CQ or HCQ.  Three differentiation endpoints were measured: 
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 (1)  lipid droplet accumulation 
 (2)  loss of Ki67 protein 
 (3)  expression of E2F-1 and c-myc cell cycle regulatory proteins 
 
3.  Hypothesis 3:  Combination of ATRA or 5-Aza-dC with CQ or HCQ will increase 
histone H3 and/or histone H4 acetylation status via inhibition of HDAC protein and 
therefore, increase RARβ2 tumor suppressor protein levels (Models 2 and 3).  MCF-7 or 
MDA-MB-231 transformed human breast cancer cell lines were used.  ATRA or 5-Aza-dC 
(Aza) was combined with either CQ or HCQ.  Three endpoints were measured: 
 (1)  acetylated histone H3 and/or histone H4 protein levels 
 (2)  HDAC protein and activity levels 
(3)  RARβ2 protein levels 
Finally, the most promising combination of agents were assessed by mass spectrometry to 
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A model for the antiproliferative and differentiating activities in breast cancer cells 
upon combination treatment with ATRA/5-Aza-dC (Aza) and CQ/HCQ.  Histone 
deacetylase (HDAC) modulates chromatin structure via the removal of acetyl groups from 
lysine residues on the N-terminal tail of histone proteins.  The (+) charged lysine residues 
are then allowed to bind very tightly to the (-) charged phosphate backbone of DNA; 
thereby, generating a more condensed chromatin structure characteristic of transcriptionally 
inactive genes involved in tumorigenesis.  On the other hand, histone acetyltransferase 
(HAT) modulates chromatin structure via the addition of acetyl groups, which neutralizes 
the (+) charged lysine residues and therefore, generates a more relaxed chromatin structure 
that allows transcription factors and RNA polymerase to access DNA and activate 
transcription of tumor suppressor genes.  The hypothesis is that upon combination therapy, 
the effects of HDAC will be reversed and therefore, ATRA or Aza will enhance the 
antiproliferative and differentiation responses to CQ/HCQ in breast cancer cells.    
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A model for gene activation by ATRA and CQ/HCQ.  In the absence of ligand, the RXR-
RAR heterodimeric complex associates with the corepressor complex:  silencing mediator of 
retinoid and thyroid hormone receptor (SMRT)-mSin3a-histone deacetylase (HDAC).  
HDAC maintains the tight association between deacetylated histones and chromatin, 
thereby, resulting in repressed gene transcription.  The hypothesis is that ATRA, the ligand 
for the RXR-RAR heterodimeric complex, and CQ/HCQ treatment will reverse these effects 
via direct or indirect inhibition of HDAC.  The corepressor complex will dissociate from the 
receptor complex with simultaneous recruitment of a coactivator complex:  CREB-binding 
protein (CBP), CBP-associated factor (p/CAF), and steroid receptor coactivator-1 (SRC-1), 
all of which will activate histone acetyltransferase (HAT).  Acetylated histones will generate 
a relaxed chromatin structure, allowing the transcriptional preinitiation complex to bind 
DNA and the ligand activated RXR-RAR heterodimeric complex to bind to its response 
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A model for gene activation by 5-Aza-dC and CQ/HCQ.  Inhibitory transcription factors 
recruit DNA methyltransferase (DNMT), resulting in the methylation of CG dinucleotides; 
thereby, silencing the promoter of the target gene.  Methyl-cytosine binding protein 2 
(MeCP2) binds the methylated CG dinucleotides.  MeCP2 interacts with the corepressor, 
mSin3, which binds to histone deacetylase (HDAC) or DNMT itself can recruit HDAC; 
thereby, perpetuating the inhibitory effect on transcription.  The hypothesis is that 5-Aza-dC, 
a DNMT inhibitor, and CQ/HCQ treatment will reverse these effects via direct or indirect 
inhibition of HDAC.  Activated transcription factors (TF) can then bind to unmethylated CG 
dinucleotides and recruit coactivators that form a complex with histone acetyltransferase 
(HAT).  DNA hypomethylation will sensitize cells to histone hyperacetylation, resulting in 


























MCF-7 cells were provided by Dr. Marc Lippman (Department of Medicine, University of 
Michigan).  MDA-MB-231 cells were provided by Dr. Mike Miller (Department of 
Biochemistry and Molecular Pharmacology, West Virginia University).  MCF-10A cells 
were purchased from American Type Culture Collection (Manassas, VA).  Clonal MCF-7 
cells, C4 and C4-12-5, were provided by Dr. Wade Welshons (Department of Veterinary 
Biomedical Sciences, University of Missouri-Columbia). 
 
1.2 Drugs 
Chloroquine, quinidine, primaquine, quinoline, trichostatin A (TSA), all-trans retinoic acid 
(ATRA), 5-aza-2’-deoxycytidine (5-Aza-dC), as well as the solvent dimethyl sulfoxide 
(DMSO) were all purchased from Sigma Chemical Company (St. Louis, MO).  
Hydroxychloroquine sulfate was provided by Mylan Pharmaceuticals, Inc. (Morgantown, 
WV).  The investigational quinoline compounds (National Service Center, NSC) were 
graciously provided by Dr. Robert Schultz (Developmental Therapeutics Program, National 
Cancer Institute, Bethesda, MD).  
 
1.3 Antibodies 
Acetylated histone H3 and H4 rabbit polyclonal antibodies were purchased from Upstate 
Biotechnology (Lake Placid, NY).  E2F-1, c-myc, and β-catenin mouse monoclonal 
antibodies, as well as RARβ2 rabbit polyclonal antibody and horse radish peroxidase-
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conjugated anti-mouse IgG (SC #2005) and anti-rabbit (SC #2004) secondary antibodies 
were all purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).   
 
2. Methods 
2.1 Cell Culture 
Permanent cell lines derived from patients with breast carcinoma were used in these studies.  
MCF-7 (passage #36-60) and MDA-MB-231 human mammary tumor cells were maintained 
in Dulbecco’s Modified Eagle’s medium (DMEM) (BioWhittaker, Walkersville, MD) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Summit Biotechnology, 
Fort Collins, CO), and 0.04mg/ml gentamicin in a 93% air/7% CO2, 370C, humidified 
incubator.  Cells were passaged weekly when 70-80% confluent at 1:5 (MCF-7) or 1:10 
ratios (MDA-MB-231).  MCF-10A immortalized human mammary epithelial cells (passage 
#1-15) were maintained in Mammary Epithelial Cell Growth Medium (MEGM) (Bio 
Whittaker) and passaged weekly at a 1:4 ratio.  Cells were counted using a hemocytometer 
and viability was determined by trypan blue exclusion (0.02% trypan blue).  
 
2.2 Oil Red-O Assay   
MCF-7 and MDA-MB-231 cells were plated on 5x5 mm2 95% ethanol-washed glass 
coverslips in 35 mm2 dishes at 2x105 and 1x105 cells per dish, respectively.  Cells were 
fixed in 10% formaldehyde and 0.2% calcium acetate in phosphate buffered saline (PBS: 
0.14M NaCl, 2.7mM KCl, 8.1mM NaHPO47H2O, 1.5mM KH2PO4) for 3 minutes and then 
transferred to an Oil Red-O (ORO) staining solution (0.5% Oil Red-O in 98% isopropanol; 
diluted 6:4 in distilled water) for 10 minutes.  Coverslips were washed briefly in tap water 
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and then counterstained with Mayer's Hematoxylin solution (Fisher, Pittsburgh, PA) for 1 
min at room temperature. After counterstaining, coverslips were rinsed again in tap water, 
washed in 0.4 % NH4OH, and then mounted using 50% glycerol (50:50 glycerol/water 
(v/v)). Lipid droplet accumulation in the cytoplasm was visualized by light microscopy 
(400x objective, Ortholux microscope, Ernst Leitz, Wetzlar, Germany).  An ORO positive 
response is defined as ≥ 10% of cells containing at least 10 lipid droplets/cell.  At least 300 
cells were counted visually.   
 
2.3 Ki67 Immunohistochemical Assay   
MCF-7 (2x105) and MDA-MB-231 (1x105) cells were plated on 5x5 mm2 95% ethanol-
washed glass coverslips in 35 mm2 dishes in DMEM/5% FBS culture medium. Cells were 
fixed in 50% acetone:50% ethanol for 10 minutes at 40C and then washed with 0.15% 
bovine serum albumin (fraction V, A-9647, Sigma) in Dulbecco’s phosphate-buffered  
saline (PBS: 0.14M NaCl, 2.7mM KCl, 8.1mM NaHPO47H2O, 1.5mM KH2PO4, pH 7.0) 
(PBS-BSA). At room temperature, coverslips were incubated with peroxidase blocking 
solution (0.3% hydrogen peroxide in methanol) for 10 minutes, rinsed with PBS-BSA, and 
incubated with 10% horse serum in PBS-BSA for 30 minutes. After incubation, primary 
antibody for Ki67 (MIB-1, cat # M7240, Dako Corporation, Glostrup, Denmark) diluted 
1:50 in PBS-BSA was added to the coverslips for 60 minutes, followed by a wash with PBS-
BSA, and incubation with secondary antibody (1:125 in PBS-BSA, biotinylated horse anti-
mouse IgG, Vector Laboratories, Burlingame, CA) for 30 minutes. Coverslips were washed 
with PBS-BSA, incubated with avidin-biotin-peroxidase reagent (Vector Laboratories) for 
30 minutes, and then washed again in PBS-BSA.  The antigen-antibody complex was 
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visualized using diaminobenzidine (Stable DAB, Research Genetics, Huntsville, AL), and 
counterstaining with Mayer’s hematoxylin (Fisher Scientific, Pittsburgh, PA).  Coverslips 
were subsequently dipped in 0.4 % NH4OH solution in tap water, dipped in 60% and 90% 
ethanol, respectively, and finally mounted using Permount (Fisher Scientific, Pittsburgh, 
PA). Ki67 negative cells were visualized by light microscopy (400x objective, Ortholux 
microscope, Ernst Leitz, Wetzlar, Germany).  Cells were individually assigned with negative 
or positive staining, and the Ki67 negative percentage of the cell population was determined 
by visual counting.  In each coverslip, at least 500 cells were counted.  (KI67 Index= % 
KI67 negative cells in drug treatment / % KI67 negative cells in control treatment)  
 
2.4 MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) Assay   
Metabolism of MTS was used as an index of cell viability. MCF-7 and MDA-MB-231 cells 
were plated at 4.0x103 and 5.0x102 cells per well in 96-well plates, respectively, in 225 µl of 
DMEM/5% FBS. After 5 days of plating, fresh growth medium (100µl DMEM/5% FBS + 
20µl CellTiter 96 AQueous one solution) (Promega, Madison, WI) was added.  Reduction  
of MTS reagent to a colored formazan product was measured after a 2 hour incubation at 
370C by an increase in absorbance at 490nm using a Spectra Max 340pc plate reader 
(Molecular Devices, Sunnyvale, CA).  The MTS assay was linear under our assay conditions 





2.5 Clonogenic Survival 
MCF-7 and MDA-MB-231 cells were plated at 6x103 cells/60 mm2 dish in 5ml DMEM/10% 
FBS and subjected to an undisturbed incubation period (7 or 5 days, respectively) in a 93% 
air/7% CO2, 370C, humidified incubator.  To visualize colonies, dishes were stained with 3 
ml of 0.5% crystal violet, 5% formalin, 50% ethanol, 0.85% NaCl for 3 minutes, then rinsed 
with tap water.  Colonies were scored using a Nikon Eclipse TS100 microscope at 20X 
magnification with ≥20 MCF-7 cells and ≥50 MDA-MB-231 cells =1 colony.  (Clonogenic 
fraction= # of colonies in control/ # of cells plated).  The clonogenic fraction of the control 
groups was set to 1.  Using Berenbaum’s equation, the drug interactions were synergistic if:  
Ac/Ae + Bc/Be < 1, where Ae and Be are the concentrations of the drugs alone, and Ac and 
Bc are the concentrations when used in combination.  Therefore, the concentration of each 
drug in the combination that produces the specified effect is expressed as a fraction of the 
concentration that produces the same effect when the drug is used alone (Berenbaum, 1978; 
Berenbaum, 1989).   
 
2.6 Western Blotting 
MCF-7 (2x106 cells/60 mm2 dish) and MDA-MB-231 (2x106 cells/60 mm2 dish) were rinsed 
once with 40C phosphate buffered saline (PBS: 0.14M NaCl, 2.7mM KCl, 8.1mM 
NaHPO47H2O, 1.5mM KH2PO4, pH 7.0).  Total cellular proteins were collected by syringe 
in 200µl boiling lysis buffer (1% SDS, 10mM Tris, pH 7.4) and chilled on ice.  Proteins 
were boiled for 5 minutes and then centrifuged at 40C, 14,000rpm in an Eppendorf 
centrifuge 5415 C (Brinkmann Instruments Inc., Westbury, NY).  Protease inhibitors, 
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aprotinin, leupeptin, and phenylmethyl sulfonyl fluoride at final concentrations of 1mM, 
1mM, and 100µM, respectively were added to the supernatant.  Protein concentrations were 
determined using the BCA assay (Pierce, Rockford, IL).  Following the BCA assay, a final 
concentration of 1µM dithiothreitol was added and protein samples were diluted in 1X 
sample buffer (0.32M Tris-HCl, 10% glycerol, 2% SDS, 0.2% bromophenol blue, 2.5% 2-
mercaptoethanol, pH 6.8) and then resolved on 10% or 15% acrylamide gels at 110 V.  
Proteins were transferred to polyvinylidene difluoride membranes (Invitrogen) at 23 V for 3 
hours. Membranes were blocked at 40C, overnight in 3% non-fat dry milk/Tris buffered 
saline (TBS: 0.02M Tris, pH7.5, 0.5M NaCl).  Membranes were then subjected to three 5 
minute washes with western wash solution (0.1% non-fat dry milk, 0.1% chick ovalbumin, 
10% 10X PBS, 1% FBS, 0.2% Tween20) and incubated with acetylated histone H3 
(1:5000), acetylated histone H4 (1:500), HDAC (1:5000), RARβ2 (1:200) rabbit monoclonal 
antibodies, or c-myc (1:100) and E2F1 (1:100) mouse monoclonal antibodies in western 
wash solution for 3½ hours.  Following primary antibody hybridizations, the membranes 
were again subjected to three 5 minute washes with western wash solution followed by one 
5 minute wash with TBS.  Membranes were hybridized with a 1:1000 dilution of anti-mouse 
or 1:5000 dilution of anti-rabbit horse radish peroxidase-conjugated secondary antibody in 
TBS for 45 minutes followed by three 10 minute washes in TBS.  Signals were visualized by 
incubating the membrane with chemiluminescent peroxidase substrate for 7 minutes (Super 
Signal West Pico Chemiluminescent Substrate, Pierce, Rockford, IL) and exposing the 
membrane to film.  Signals were quantitated by FluoroChem (Alpha Innotech, San Leandro, 
CA) spot densitometry using automatic background subtraction. 
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2.7 HDAC Fluorescent Activity Assay 
Drugs were screened for the ability to directly inhibit histone deacetylase (HDAC) activity 
using the HDAC Fluorescent Activity Assay (Drug Discovery kit cat # AK-500, BIOMOL 
Research Laboratories, Inc. Plymouth Meeting, PA).  This assay system measures histone 
deacetylase activity present in a commercial HeLa (human cervical cancer cell line) cell 
nuclear extract, which is rich in HDAC activity.  Reactions were performed at room 
temperature in a 96-well microtiter plate.  10µl of drugs were added into appropriate wells to 
attain a final MTS IC50 concentration, followed by 15µl of diluted HeLa nuclear extract.  
HDAC reactions were initiated by adding 25µl of diluted substrate to each well and mixing 
thoroughly.  The reactions were performed for 10 minutes after which 50µl of the developer 
was added into each well of the microtiter plate to stop the HDAC reactions. The plate was 
subsequently incubated at room temperature for a final 10 minutes.  HDAC fluorescent 
activity was measured using a microtiter-plate reading fluorimeter at a 360nm excitation and 
460nm emission wavelength (CytoFluor, Muti-well Plate Read Series 4000, PerSeptive 
Biosystems, Farmingham, MA)  Reactions were linear for 30 minutes under these assay 
conditions. 
 
2.8 HAT Assay 
Drugs were screened using an indirect ELISA Assay (HAT Assay Kit, Upstate 
Biotechnology, Lake Placid, NY) for the detection of acetyl residues on biotinylated Histone 
H3 or Histone H4 substrate peptides.  Acetylated Histone H3 or Histone H4 peptides were 
used as positive controls.  Wells were pre-coated with the substrate peptides and then 
reactions were initiated by the addition of 75ng of recombinant PCAF, an active source of 
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histone acetyltransferase enzyme, in the presence of 100µM Acetyl-CoA and HAT assay 
buffer.  Wells were then incubated in the presence of anti-acetyl-Lysine (1:250) rabbit 
monoclonal antibody for 1.5 hours and anti-rabbit horse radish peroxidase-conjugated 
secondary antibody for 30 minutes in TBS containing 3% BSA, followed by 
tetramethylbenzidine substrate mixture for 10 minutes.  Finally, the HRP reactions were 
stopped by the addition of 1M sulfuric acid.  HAT activity was measured immediately using 
a Spectra Max 340pc plate reader (Molecular Devices, Sunnyvale, CA). 
 
2.9 Histone Extraction 
MCF-7 and MDA-MB-231 breast cancer cells were plated at a density of 1X107cells/T-162 
flask and 8X106cells/T-162 flask, respectively, using DMEM supplemented with 5% FBS 
and allowed to attach for 3 hours before ATRA or 5-Aza-dC treatment.  After 24 hours of 
ATRA or 5-Aza-dC treatment, chloroquine, hydroxychloroquine, or TSA were added for the 
indicated time points.  Cells were then harvested, rinsed with ice cold PBS, scraped into ice-
cold lysis buffer (10mM Tris-HCl, 50mM sodium bisulfite, 1% Triton-X-100 (v/v), 10mM 
MgCl2, 8.6% sucrose, pH 6.5) and the nuclei released by Dounce homogenization.  The 
nuclei were collected using Sorvall SS-34 rotor centrifugation and the histones were 
extracted from the crude nuclear pellets.  The pellets were resuspended in sterile water and 
0.4N H2SO4 and incubated at 4°C for 1 hour.  Following centrifugation, the supernatant 
containing the extracted histones were mixed with acetone.  The precipitate was obtained 
after an overnight incubation at -20°C.  The acid-soluble histone fraction was dissolved in 
60µl of dH2O and stored in -70°C.  Histone protein concentrations were determined using 
the BCA assay (Pierce, Rockford, IL) and bovine serum albumin as a standard.  Following 
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the BCA assay, a final concentration of 1µM dithiothreitol was added to the protein samples.  
Equal amounts of histones were electrophoresed on SDS-15% polyacrylamide gels.  
Molecular weights of the proteins were estimated based on the relative migration with 
colored molecular weight protein markers (RPN756, Amersham Pharmacia Biotech Inc.)  
Anti-acetylated histone H3 or H4 rabbit polyclonal antibodies were used for the detection of 
histone acetylation.     
 
2.10 Mass Spectrometry 
Equal amounts of acid extracted histone proteins from MCF-7 cells were electrophoresed on 
SDS-15% polyacrylamide gels.  Histones H3 and H4 were confirmed by Coomassie Blue 
staining (0.25% Coomassie R-250, 45% methanol, 45% dH2O, and 0.1% acetic acid) for 2 
hours and destaining (45% methanol, 45% dH2O, and 0.1% acetic acid) for 6 hours while 
changing the destain every 2 hours.  Histones H3 and H4 bands were excised from the gel 
and placed into 0.65 mL low-binding microcentrifuge tubes.  The bands were digested in-gel 
with 50µl of 100ng of the endoprotease trypsin in 25mM NH4HCO3 overnight at 37°C.  
Histones were separated using  reverse-phase HPLC (A= 0.1% Acetic Acid; B= Acetonitrile 
with 0.1% Acetic Acid; Gradient was 5-50% B over 40 minutes, 50-90% B in one minute) 
C18 column [360 micron O.D. x 75 micron I.D. fused silica with 10 centimeters of 5 micron 
particle size; C18 packing material with 100 Angstrom pore size (from Phenomenex)].  
Peptides were co-crystallized with equal volumes of matrix (α-cyano-cinnamic acid in 
49.5% ethanol, 49.5% acetonitrile, and 0.1% trifluoroacetic acid).  Samples were analyzed 
on a ThermoFinnigan LCQ Deca XP Plus ion trap with a flow rate of 300 nL per minute 
using a spray voltage of 1.5 kV and a capillary temperature of 160°C to attain a positive 
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ionization mode.  Collision energy was set at 35% in order to perform a full scan MS 
followed by MS/MS of the three most abundant ions.  MS/MS spectra were searched against 
International Protein Index (IPI) human database using Sequest Software.  Acetylation sites 
were identified using a differential modification of 42 Daltons added to Lysine residues. 
 
 2.11 Statistical Analysis  
Statistically significant differences (P<0.05) were determined using one-way analysis of 
variance (ANOVA).  This was followed by the Dunnett’s test for comparison of multiple 






































Chapter 1.  Augmentation of the Differentiation Response using all-trans-Retinoic Acid 
in Combination with Chloroquine or Hydroxychloroquine 
 
1.1  Selective Toxicity of Chloroquine and Hydroxychloroquine.  Two cell lines 
commonly used as in vitro breast tumor cell models were chosen for experiments:  MCF-7 
(estrogen receptor, ER+) and MDA-MB-231 (ER-).  Toxicity levels of both chloroquine and 
hydroxychloroquine were assayed in the MCF-7 and MDA-MB-231 breast cancer cell lines 
and compared to the MCF-10A normal mammary epithelial cells using the MTS assay.  
Mitochondrial metabolism of the substrate, MTS, is a measure of cell survival and can be 
applied extensively to many cell types.  The assay measures dehydrogenase enzyme activity 
found in metabolically active cells.  Cell survival was monitored using a 96-well plate 
format in which this tetrazolium substrate gets chemically reduced by cells into a colored 
formazan product that absorbs light at 490 nm.  Concentration-response analysis curves 
were generated to reveal significantly lower IC50 values in the breast cancer cell lines versus 
the normal human mammary epithelial cells, indicating that these quinolines were more 
toxic to the breast cancer cells (Table 1).  The estimated growth inhibitory concentrations 
(IC25 and IC50) for chloroquine and hydroxychloroquine were then used in subsequent 

































Table 1.  Growth inhibitory concentrations for Chloroquine and Hydroxychloroquine.   
MDA-MB-231 and MCF-7 breast cancers cells, as well as MCF-10A normal breast cells, 
were plated at 5.0x102, 4.0x103, and 2.0x103 cells per well in 96-well plates, respectively.    
IC25 and IC50 growth inhibitory concentrations represent the inhibition of mitochondrial 
metabolism of MTS following a 48hour exposure to each compound.  Data are the mean 
±SEM of IC50 data in n=3 independent experiments performed with 10 concentrations of 
each compound in triplicate.  Statistically significant differences between cell lines and 
between chloroquine and hydroxychloroquine from the same cell lines are indicated: 
 
*  Statistically significant differences from MCF-10A cell line (p<0.05). 
#  Statistically significant differences from MCF-7 cell line (p<0.05). 
c  Statistically significant differences from chloroquine in same cell line (p<0.05). 
h  Statistically significant differences from hydroxychloroquine in same cell line (p<0.05). 
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1.2  Chloroquine and Hydroxychloroquine caused accumulation of cytoplasmic lipid 
droplets in MCF-7 and MDA-MB-231 breast cancer cells but not in MCF-10A normal 
mammary epithelial cells.  Since chloroquine and hydroxychloroquine displayed selective 
toxicity in breast cancer cells, it was necessary to determine whether these antiproliferative 
agents were also capable of inducing cell differentiation.  Oil Red-O is a lipophilic red dye 
used to stain neutral lipids in cells.  Cytoplasmic lipid droplets are the immediate precursors 
of milk lipids and their formation is also one of the earliest phenotypes of differentiating 
mammary epithelial cells (Wu et al., 2000).  As evidence of cellular differentiation, both 
chloroquine and hydroxychloroquine led to an enhanced accumulation of cytoplasmic lipid 
droplets detected by Oil Red-O staining in both the MCF-7 and MDA-MB-231 breast cancer 
cell lines after 48 hours of treatment, while neither compound caused elevated lipid droplet 
formation in MCF-10A normal human mammary epithelial cells (Figure 5).  Direct 
visualization of the cellular morphology of the treated cells versus the control cells indicated 
that the breast cancer cells also displayed an enlarged cytoplasm, which is characteristic of 

















Figure 5.  Chloroquine and Hydroxychloroquine cause accumulation of cytoplasmic 
lipid droplets in MCF-7 and MDA-MB-231 breast cancer cells but not in MCF-10A 
normal mammary epithelial cells.  MCF-7 and MDA-MB-231 (2x105 cells /35 mm2 dish) 
and MCF-10A (1x105 cells /35 mm2 dish) were grown on glass cover slips and treated with 
chloroquine or hydroxychloroquine at their respective IC25 values, or solvent (control, 
DMSO) for 48 hours.  Cells were then stained with the Oil Red-O stain (red dots in the 
cytoplasm) and counterstained with the Mayer’s hematoxylin stain (blue nuclei). 
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1.3  Chloroquine increased the G0 cell population indicated by loss of Ki67 antigen in 
MCF-7 breast cancer cells.  Primary markers for cellular differentiation include changes in 
cellular morphology as characterized by the accumulation of cytoplasmic lipid droplets 
(Figure 5) and exit from the cell cycle.  This latter marker for cellular differentiation, cell 
cycle arrest in G1, can be measured by Ki67 histochemistry.  Ki67 is a large nuclear protein 
expressed in all proliferating cells, in normal as well as in tumor cells.  It is also expressed 
during all active phases of the cell cycle (G1, S, G2, and M-phases), but is absent in resting, 
or differentiating, cells (G0 phase) (Scholzen and Gerdes, 2000).  Therefore, it makes it an 
excellent marker in determining the growth fraction of a given cell population and is used 
widely as a diagnostic tool in distinct neoplasms.  For this reason, Ki67 protein was 
measured in MCF-7 breast cancer cells after 48 hours of treatment with chloroquine (Figure 
6).  Compared to the control, which primarily has brown staining for the presence of Ki67 
protein, the chloroquine-treated group contained many more blue cells indicative of cells 
that have arrested in G0.   


































Figure 6.  Ki67 immunohistochemical staining of MCF-7 cells.  Control or 33µM 
chloroquine-treated MCF-7 cells were grown on glass cover slips for 48 hours and then 
assayed for Ki67 immunoreactivity.  Brown staining indicates the presence of Ki67 protein 
and cycling cells.  Blue staining is indicative of cells that have exited from the cell cycle into 









1.4  MCF-7 and MDA-MB-231 cell survival in response to Chloroquine and ATRA.  So 
far, both chloroquine and hydroxychloroquine showed to be promising candidates for breast 
cancer prevention and treatment.  To identify whether the use of a drug combination 
modulating epigenetic events would lower the concentration of chloroquine or 
hydroxychloroquine needed to produce the differentiation response, all-trans-Retinoic acid 
(ATRA) was used in subsequent studies.  First, as a screening assay, the mitochondrial 
metabolism of MTS was used as an index for cell survival.  Cells were pretreated with 
ATRA 48 hours before treatment with chloroquine (Figure 7).  Two different concentrations 
of chloroquine were used in this experiment:   MCF-7 IC50 value, 33µM, and 10µM, which 
is close to the estimated MDA-MB-231 IC50 value as well as the clinically safe 
concentration with no known side effects (Singhal et al., 1989).  The combination of ATRA 
with chloroquine sensitized both the MCF-7 and MDA-MB-231 cell lines to growth 
inhibition.  ATRA (1µM) significantly decreased cell survival in both cell lines when used 
in combination with the IC50 concentration and the clinically safe concentration of 
chloroquine.  These results support the hypothesis that combination of ATRA with 












Figure 7.  Inhibition of MCF-7 and MDA-MB-231 cell survival.  On day 0, MCF-7 and 
MDA-MB-231 cells were plated at 4.0x103 and 5.0x102 cells per well in 96-well plates, 
respectively, in 225 µl of DMEM/5% FBS for 5 days.  Cells were incubated and ATRA was 
added on day 1, followed by the addition of chloroquine (CQ) on day 3.  On day 5, 48 hours 
after CQ addition, mitochondrial metabolism of MTS was measured after a 2 hour 
incubation at 370C by an increase in absorbance at 490nm using a Spectra Max 340pc plate 
reader (Molecular Devices, Sunnyvale, CA).  Data are the mean ±SEM of 3 independent 
experiments performed with 5 replicates per treatment.  Statistically significant differences 
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1.5  Combination of Chloroquine or Hydroxychloroquine with ATRA inhibited growth 
of human breast cancer cell lines.  Although the MTS assay is a good screening tool for 
measuring antiproliferative activity, the effects of chloroquine or hydroxychloroquine with 
ATRA on cell growth and viability were also measured by visually counting the number of 
viable cells in MCF-7 and MDA-MB-231 breast cancer cell lines and comparing them to 
MCF-10A normal epithelial cells (Figure 8).  MCF-7, MDA-MB-231, and MCF-10A were 
replica-plated in DMEM/5% FBS (tumor cells) or MEGM (normal cells) medium and 
pretreated with 1µM ATRA 24 hours before treatment with MCF-7 IC50 levels of 
chloroquine or hydroxychloroquine.  Cell growth was counted using a hemocytometer and 
viability was assessed by trypan blue exclusion on the indicated days to generate growth 
curves.  The data suggest that while chloroquine and hydroxychloroquine alone suppressed 
growth of the breast cancer cell lines, the combination of these antimalarials with ATRA 
lead to an enhanced growth inhibition.  The combination of chloroquine with ATRA lead to 
84% (Day 5) and 78% (Day 8) maximum reduction in growth of MDA-MB-231 and MCF-7 
cells, respectively.  The combination of hydroxychloroquine with Aza caused 89% (Day 5) 
and 82% (Day 8) maximum reduction in growth of MDA-MB-231 and MCF-7 cells, 
respectively.  Chloroquine and hydroxychloroquine also inhibited the growth of MCF-10A 
cells.  Perhaps the antiproliferative effect seen in the MCF-10A cells may be due to the fact 
that they are immortalized.  Nevertheless, ATRA did not sensitize the MCF-10A cells to 
further growth inhibition when combined with these antimalarials.  These results support the 
hypothesis that combination of ATRA with chloroquine or hydroxychloroquine would 
augment the antiproliferative effects of the antitumor quinolines.  ATRA in combination 








Figure 8.  Inhibition of growth in MCF-7 and MDA-MB-231 breast cancer cells 
compared to MCF-10A normal mammary epithelial cells.  MCF-7 or MDA-MB-231 
cells (2x105/35 mm2 dish), and MCF-10A normal cells (1x105/35 mm2 dish) were plated and 
allowed to attach for 3 hours before ATRA addition (Day 0). On day 1, cells were incubated 
in the presence of solvent (control, DMSO) or MCF-7 IC50 levels of chloroquine (CQ) or 
hydroxychloroquine (HCQ).  Cells were harvested and viable cells were counted on the 
indicated days to generate the growth curves. Data represent the mean of duplicate 
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1µM ATRA + 57µM HCQ
Figure 8A.  MDA-MB-231 

























































1.6  Combination of Chloroquine or Hydroxychloroquine with ATRA reduced tumor 
cell clonogenic survival.  The MTS assay offers broad applicability and is suitable as a 
screening assay for drug activity.  Cell growth curves are more reliable and are a better in 
vitro tool for the depiction of cell survival.  Nevertheless, it is pertinent to have a better 
appreciation for in vivo conditions in the breast cancer cell lines by using a much more 
sensitive assay for tumor cell survival.  Since cancer cells undergo unlimited division and 
even a single cell may be the source of a repopulating clone, successful cancer therapy must 
assure the eradication of all clonogenic tumor cells from the organism.  The clonogenic 
survival assay is a classical method for testing cellular sensitivity to different doses of 
cytotoxic and genotoxic anticancer agents in vitro.  It is used to measure the fraction of cells 
able to form colonies.  This assay seems to be one of the most sensitive tests for predicting 
the responsiveness of a tumor to clinical treatment (Kumala et al., 2003; West et al., 1997).  
Thus, this method was adopted to predict the effect of chloroquine and hydroxychloroquine 
upon pretreatment with ATRA on tumor cell survival (Figure 9 and Table 2). 
MDA-MB-231 and MCF-7 cell clonogenic survival was assessed using crystal violet 
staining and visual colony inspection.  Because MDA-MB-231 cells have a more rapid 
doubling time compared with MCF-7 cells, MDA-MB-231 cells were allowed a shorter five 
day incubation period prior to end point analysis.  Overall, the clonogenic survival assays 
showed that the combination of ATRA with the quinolines significantly decreased breast 
cancer clonogenic survival more than either chloroquine or hydroxychloroquine alone.  
Table 2 shows that clonogenic survival of MDA-MB-231 cells exposed to combination of 
1µM ATRA with chloroquine for seven days, was reduced by 82% compared to control 
cells exposed to solvent alone, whereas combination of 1µM ATRA with 
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hydroxychloroquine was reduced by 92%.  In MCF-7 cells, clonogenic survival was reduced 
by 76% upon combination treatment with ATRA and chloroquine and by 83% with ATRA 
and hydroxychloroquine.   
The results were recalculated using the method of Berenbaum (Berenbaum, 1978; 
Berenbaum, 1989) to test for synergy.  The interaction of ATRA with chloroquine or 
hydroxychloroquine showed to be synergistic in both the MDA-MB-231 and MCF-7 breast 
cancer cell lines.  These results support the hypothesis that combination of ATRA with 
chloroquine or hydroxychloroquine would augment the antiproliferative effects of the 
antitumor quinolines.  Once again, ATRA in combination with hydroxychloroquine showed 
to have the most promise in decreasing tumor cell survival.  Clonogenic survival was also 
assayed in the MCF-10A normal epithelial cells (n=2); however, these cells did not form 
































Figure 9.  MCF-7 cell clonogenic survival.  Cells were pretreated with either solvent 
(control, DMSO) or chloroquine (CQ, 33µM) ± ATRA (1µM) as performed for the growth 
curves.  6x103 pretreated cells were plated in 60 mm2 dish and subjected to 7 days of an 
undisturbed incubation period.  Colonies were visualized by staining the dishes with 3 ml of 
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       0.473* 
 
       0.452* 
 
       CQ 
 
       0.310*,a 
 
       0.554* 
 
       HCQ 
 
       0.197*,a,b 
 
       0.325*,a,b 
 
       ATRA + CQ 
 
       0.180*,a,b 
 
       0.239*,a,b 
 
       ATRA + HCQ 
 
       0.084*,a,b,c,d 
 
       0.170*,a,b,c 
 
 
Table 2.  Tumor cell clonogenic survival using ATRA.  MDA-MB-231 or MCF-7 cells 
(2x105/35 mm2 dish) were plated and allowed to attach for 3 hours before addition of solvent 
(control, DMSO) or MCF-7 IC50 levels of chloroquine (CQ, 33µM) or hydroxychloroquine 
(HCQ, 57µM) ± ATRA (1µM).  MDA-MB-231 and MCF-7 cells were harvested on days 3 
and 4, respectively, and replated at a cloning cell density of 6x103 cells/60 mm2 dishes in 
5ml DMEM/10% FBS and subjected to an undisturbed incubation period (5 or 7 days, 
respectively).  Colonies were visualized by staining the dishes with 3 ml of 0.5% crystal 
violet, 5% formalin, 50% ethanol, 0.85% NaCl for 3 minutes, then rinsing with tap water.  
Colonies were scored using a Nikon Eclipse TS100 microscope at 20X magnification with 
≥20 MCF-7 cells and ≥50 MDA-MB-231 cells =1 colony.  The data are represented as 
clonogenic fractions, where the clonogenic fraction of the control groups was set to equal 1.  
Data are the mean of 3 independent experiments performed in duplicates. 
  
*  Statistically significant differences from the control (p<0.05). 
a  Statistically significant differences from ATRA alone (p<0.05). 
b  Statistically significant differences from CQ alone (p<0.05). 
c  Statistically significant differences from HCQ alone (p<0.05). 
d  Statistically significant differences from ATRA + CQ (p<0.05). 
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1.7  Combination of Chloroquine or Hydroxychloroquine with ATRA caused  
enhanced accumulation of cytoplasmic lipid droplets in MCF-7 and MDA-MB-231 
breast cancer cells.  The data presented above showed that the combination of chloroquine 
or hydroxychloroquine with ATRA reduced cell and clonogenic survival in human breast 
cancer cells more than either quinoline alone.  Therefore, it was necessary to determine 
whether ATRA in combination with chloroquine or hydroxychloroquine was also capable of 
augmenting the differentiation response.  As evidence of cellular differentiation, 
pretreatment with 1µM ATRA led to an enhanced accumulation of cytoplasmic lipid 
droplets detected by Oil Red-O (ORO) staining in both the MCF-7 and MDA-MB-231 
breast cancer cell lines after 24 hours of quinoline treatment (Figure 10).  The differentiation 
response was greater than either chloroquine or hydroxychloroquine alone at both the IC25 
and IC50 levels and was significantly greater than the control (DMSO).  
 MDA-MB-231 cells treated with chloroquine alone at IC25 and IC50 showed a 74% 
and 88% increase in lipid droplets, respectively, compared with 89% and 95% increase in 
cells pretreated with ATRA.  Hydroxychloroquine alone showed a 76% and 83% increase in 
lipid droplets at its MDA-MB-231 IC25 and IC50 values, respectively, compared with 92% 
and 93% increase in cells pretreated with ATRA.   
MCF-7 cells treated with chloroquine alone at IC25 and IC50 showed a 74% and 85% 
increase in lipid droplets, respectively, compared with 93% and 92% increase in cells 
pretreated with ATRA, while hydroxychloroquine alone showed a 72% and 79% increase in 
lipid droplets at IC25 and IC50 values, respectively, compared with 88% and 90% increase in 
cells pretreated with ATRA.  
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In summary, these results support the hypothesis that the differentiation response by 
chloroquine or hydroxychloroquine, would be augmented when combined with 1µM ATRA.  
Pretreatment of MDA-MB-231 or MCF-7 breast cancer cells with ATRA in combination 
with treatment with the IC25 values of either chloroquine or hydroxychloroquine, showed a 
greater percentage of ORO positive cells than either of the quinoline alone at their respective 
IC50 values.  Therefore, combination therapy seems to lower the concentration of 
chloroquine or hydroxychloroquine needed to achieve the same differentiation response.  
ATRA in combination with either chloroquine or hydroxychloroquine showed to have 




















Figure 10.  Oil Red-O (ORO) Histochemistry: Enhanced accumulation of cytoplasmic 
lipid droplets in MCF-7 and MDA-MB-231 breast cancer cells using Chloroquine or 
Hydroxychloroquine in combination with ATRA.  A.) MCF-7 (2x105 cells /35 mm2 dish) 
were plated and treated with 1µM ATRA.  24 hours later, cells were treated with solvent 
(control, DMSO) or chloroquine (CQ, IC25=14µM) for another 24 hours and then stained 
with the ORO stain (red dots in the cytoplasm) and counterstained with the Mayer’s 
hematoxylin stain (blue nuclei).  B.) MCF-7 and MDA-MB-231 cells were plated on 5x5 
mm2 95% ethanol-washed glass coverslips in 35 mm2 dishes at 2x105 and 1x105 cells per 
dish, respectively.  Cells were pretreated with 1µM ATRA for 24 hours and then treated 
with chloroquine (CQ) or hydroxychloroquine (HCQ) at their respective IC50 and IC25 
values for another 24 hours.  The ORO assay was performed and lipid droplet accumulation 
in the cytoplasm was visualized by light microscopy.  At least 300 cells were counted 
visually.  Data represents the mean of 3 independent experiments (+/- SEM).  Statistically 
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1.8  Combination of Chloroquine or Hydroxychloroquine with ATRA elevated the 
Ki67 index.  Since combination treatment of chloroquine or hydroxychloroquine with 
ATRA enhanced the accumulation of cytoplasmic lipid droplets in both the MCF-7 and 
MDA-MB-231 breast cancer cell lines, it was necessary to see whether it also increased the 
G0 cell population as measured by loss of Ki67 antigen in order to further validate the 
differentiation response.  Ki67 protein was measured in both MCF-7 and MDA-MB-231 
breast cancer cells after 24 hours of treatment with chloroquine or hydroxychloroquine at 
IC25 and IC50 MTS values ± 24 hour pretreatment with 1µM ATRA (Figure 11).  The results 
showed that the combination of ATRA with either chloroquine or hydroxychloroquine 
elevated the Ki67 index in both the MCF-7 and MDA-MB-231 breast cancer cells.  The 
increased Ki67 index is indicative of a greater percentage of cells that have exited from the 
cell cycle into a differentiated Ki67 negative state.  The differentiation response was greater 
than either chloroquine or hydroxychloroquine alone at both the IC25 and IC50 levels.   
MDA-MB-231 cells treated with chloroquine alone at IC25 and IC50 showed a Ki67 
index of 6.1 and 9.7, respectively, compared with an increased Ki67 index of 11.7 and 14.4 
in cells pretreated with ATRA.  Hydroxychloroquine alone showed a Ki67 index of 7.6 and 
9.2 at its MDA-MB-231 IC25 and IC50 values, respectively, compared with an increased 
Ki67 index of 12.2 and 14.0 in cells pretreated with ATRA.   
MCF-7 cells treated with chloroquine alone at IC25 and IC50 showed a Ki67 index of 
6.9 and 8.3, respectively, compared with an increased Ki67 index of 8.9 and 9.6 in cells 
pretreated with ATRA, while hydroxychloroquine alone showed a Ki67 index of 5.8 and 6.6 
at IC25 and IC50 values, respectively, compared with an increased Ki67 index of 6.6 and 8.2 
in cells pretreated with ATRA.  
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These experiments provide evidence that the differentiation response measured by 
increase in the G0 cell population can be augmented with pretreatment with 1µM ATRA 
more than either chloroquine or hydroxychloroquine alone.  Although the antitumor 
antimalarials alone displayed an enhanced Ki67 index, pretreatment with ATRA lowered the 
concentration of chloroquine or hydroxychloroquine needed to achieve the same response.  
Pretreatment of MDA-MB-231 or MCF-7 breast cancer cells with ATRA in combination 
with treatment with the IC25 values of either chloroquine or hydroxychloroquine showed a 





















Figure 11.  KI67 Histochemistry: Increase in G0 cell population in both MCF-7 and 
MDA-MB-231 breast cancer cells treated with Chloroquine or Hydroxychloroquine in 
combination with ATRA.  A.) MCF-7 (2x105 cells/35 mm2 dish) were pretreated with 1µM 
ATRA 24 hours prior to addition of solvent (control, DMSO) or chloroquine (CQ, 
IC25=14µM).  24 hours later, Ki67 immunoreactivity was assayed.  Brown staining indicates 
the presence of Ki67 protein and cycling cells.  Blue staining indicates Ki67 negative or G0 
cells.  B.) MCF-7 and MDA-MB-231 cells were plated on 5x5 mm2 95% ethanol-washed 
glass coverslips in 35 mm2 dishes at 2x105 and 1x105 cells per dish, respectively.  Cells were 
pretreated with 1µM ATRA 24 hours prior to chloroquine (CQ) or hydroxychloroquine 
(HCQ) addition at their respective IC50 and IC25 values.  KI67 immunoreactivity was 
assayed 24 hours post-antimalarial treatment.  KI67 negative percentage of the cell 
population was determined by visual counting. At least 500 cells were counted. (KI67 
Index= % KI67 negative cells in drug treatment / % KI67 negative cells in control 
treatment).  Data represents the mean of 3 independent experiments (+/- SEM).  Statistically 
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1.9  Downregulation of E2F-1 protein in MCF-7 breast cancer cells in response to 
Chloroquine and ATRA.  Alterations in the regulation of a key cell cycle regulatory 
protein, E2F-1, was measured by Western blotting (Figure 12).  E2F-1, which is tightly 
bound to the retinoblastoma (Rb) protein, interacts with HDAC to enhance cell cycle 
progression by stimulating the G1-S cell cycle transition (Martinez-Balbas et al., 2000).  In 
order for cells to undergo differentiation, downregulation of E2F-1 is an essential 
precondition (Yamasaki et al., 1996); therefore, E2F-1 protein levels were assessed in order 
to confirm G1 cell cycle arrest as seen in the data above.  Although the clinically safe 
concentration of ATRA is 10µM, lower (1µM) and higher (100µM) concentrations of 
ATRA were tested in combination with the IC50 value of chloroquine in order to assess:  (1) 
if lower concentrations would be permitted for maximum therapeutic effects, (2) or if the 
response is altered at higher concentrations.  The lower concentration of ATRA (1µM) had 
been used in all of the previous experiments; however, 10µM and 100µM ATRA are also 
used in subsequent studies for a better understanding of the differentiation response.  E2F-1 
protein was downregulated in MCF-7 breast cancer cells in response to combination 
treatment of chloroquine and ATRA.  Chloroquine caused a 60%, 67%, and 72% decrease in 
E2F-1 protein levels when combined with 1,10, and 100µM ATRA, respectively.  The 
response was statistically significant, but yet a modest effect.  Nevertheless, it supports the 
hypothesis that that combination of ATRA with chloroquine would augment the 










Figure 12.  E2F-1 protein expression in MCF-7 cells following treatment with 
Chloroquine ± ATRA.  MCF-7 (2x106 cells/60 mm2 dish) were pretreated with 1, 10, or 
100 µM ATRA for 24 hours before chloroquine (CQ, IC50=33µM) addition for another 24 
hours.  Total cellular proteins were isolated and 80µg of whole cell extract proteins were 
resolved on a 10% acrylamide gel and analyzed by Western blot.  Signals were quantitated 
by FluoroChem (Alpha Innotech, San Leandro, CA) spot densitometry using automatic 
background subtraction after normalization to β-catenin levels.  Data shown represents the 
mean of three experiments ±SEM.   
 
*  Statistically significant differences from the control (p<0.05). 
a  Statistically significant differences from CQ alone (p<0.05). 
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1.10  Downregulation of c-myc protein in MCF-7 breast cancer cells in response to 
Chloroquine and ATRA.  c-myc, a protooncogene which codes for proteins that stimulate 
cell division, is a key regulator of cell cycle progression, cell differentiation, and apoptosis 
(Melkoumian et al., 2002; Spaventi et al., 1993).   It is hypothesized that in order for cells to 
undergo differentiation, downregulation of c-myc protein may be an essential step in 
controlling the cell cycle regulatory profile.  In order to confirm the cellular differentiation 
response seen in the above results, alterations in the level of c-myc protein was measured by 
Western blotting (Figure 13).  c-myc protein was downregulated in MCF-7 breast cancer 
cells in response to combination treatment of chloroquine and ATRA.  Chloroquine caused a 
66%, 69%, and 79% decrease in c-myc protein levels when combined with 1,10, and 100µM 
ATRA, respectively; therefore, the cells experienced an enhanced downregulation of c-myc 
protein with increased concentration of ATRA.  The effect was modest even though the 
response was statistically significant.  Nevertheless, the results support the hypothesis that 
that combination of ATRA with chloroquine would augment the differentiation response as 















Figure 13.  c-myc protein expression in MCF-7 cells following treatment with 
Chloroquine ± ATRA.  MCF-7 (2x106 cells/60 mm2 dish) were pretreated with 1, 10, or 
100 µM ATRA for 24 hours before chloroquine (CQ, IC50=33µM) addition for another 24 
hours.  Total cellular proteins were isolated and 80µg of whole cell extract proteins were 
resolved on a 10% acrylamide gel and analyzed by Western blot.  Signals were quantitated 
by FluoroChem (Alpha Innotech, San Leandro, CA) spot densitometry using automatic 
background subtraction after normalization to β-catenin levels.  Data shown represents the 
mean of three experiments ±SEM.   
 
*  Statistically significant differences from the control (p<0.05). 
a  Statistically significant differences from CQ alone (p<0.05). 
b  Statistically significant differences from 1µM ATRA + CQ (p<0.05). 
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Chapter 2.  Augmentation  of  the  Differentiation  Response  using  5-Aza-2’-
deoxycytidine in Combination with Chloroquine or Hydroxychloroquine 
 
2.1  Combination of Chloroquine or Hydroxychloroquine with 5-Aza-dC inhibited 
growth of human breast cancer cell lines.  To identify whether the use of another drug 
combination modulating epigenetic events would lower the concentration of chloroquine or 
hydroxychloroquine needed to produce the differentiation response, 5-Aza-dC (Aza) was 
used in subsequent studies.  The antiproliferative effects of both CQ or HCQ in combination 
with Aza were first assessed.  The effects of these quinolines with Aza on cell growth were 
also measured by visually counting the number of viable cells in MCF-7 and MDA-MB-231 
breast cancer cell lines and comparing them to MCF-10A normal epithelial cells (Figure 14).  
MCF-7, MDA-MB-231, and MCF-10A were replica-plated in DMEM/5% FBS (tumor 
cells) or MEGM (normal cells) medium and treated with MCF-7 IC50 levels of chloroquine 
or hydroxychloroquine and the lowest concentration of Aza (1µM).  Cells growth was 
counted using a hemocytometer and viability was assessed by trypan blue exclusion on the 
indicated days to generate growth curves.  The results showed that while chloroquine alone 
suppressed growth in the breast cancer cell lines, the combination of chloroquine with Aza 
lead to a 58% (Day 4) and 55% (Day 6) maximum reduction in growth of MDA-MB-231 
and MCF-7 cells, respectively.  Hydroxychloroquine alone also inhibited growth in the 
breast cancer cell lines; however, the combination of hydroxychloroquine with Aza caused a 
83% (Day 4) and 65% (Day 8) maximum reduction in growth of MDA-MB-231 and MCF-7 
cells, respectively.  While chloroquine and hydroxychloroquine also inhibited the growth of 
MCF-10A normal cells, Aza did not sensitize the normal cells to further growth inhibition 
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when combined with these antimalarials.  Nevertheless, these results support the hypothesis 
that combination of Aza with chloroquine or hydroxychloroquine would augment the 
antiproliferative effects of the antitumor quinolines.  Aza in combination with 
hydroxychloroquine showed to have the most promise in decreasing cell survival, especially 


























Figure 14.  Inhibition of growth in MCF-7 and MDA-MB-231 breast cancer cells 
compared to MCF-10A normal mammary epithelial cells.  MCF-7 or MDA-MB-231 
cells (2x105/35 mm2 dish), and MCF-10A normal cells (1x105/35 mm2 dish) were plated and 
allowed to attach for 3 hours before 5-Aza-dC (Aza) addition (Day 0). On day 1, cells were 
incubated in the presence of solvent (control, DMSO) or MCF-7 IC50 levels of chloroquine 
(CQ) or hydroxychloroquine (HCQ).  Cells were harvested and viable cells were counted on 
the indicated days to generate the growth curves. Data represents the mean of duplicate 
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Figure 14A.  MDA-MB-231 
 
   









Figure 14B.  MCF-7 
 
 










Figure 14C.  MCF-10A 
                               







2.2  Combination of Chloroquine or Hydroxychloroquine with 5-Aza-dC reduced 
tumor cell clonogenic survival.  The effect of chloroquine and hydroxychloroquine with 
Aza on tumor cell survival is shown in Table 3.  MDA-MB-231 and MCF-7 cell clonogenic 
survival was assessed using crystal violet staining and visual colony inspection.  Although, 
Aza did not have a great effect in reducing tumor cell clonogenic survival in MCF-7 cells, 
the combination of Aza with the quinolines significantly decreased breast cancer clonogenic 
survival more than either chloroquine or hydroxychloroquine alone in the MDA-MB-231 
breast cancer cells.  Clonogenic survival of MDA-MB-231 cells exposed to combination of 
1µM Aza with chloroquine for seven days, was reduced by 82% compared to control cells 
exposed to solvent alone, whereas combination of 1µM Aza with hydroxychloroquine was 
reduced by 91%.  On the other hand, in MCF-7 cells clonogenic survival was reduced by 
56% upon combination treatment with Aza and chloroquine and by 68% with Aza and 
hydroxychloroquine compared to control cells exposed to solvent. 
The results were recalculated using the method of Berenbaum (Berenbaum, 1978; 
Berenbaum, 1989) to test for synergy.  The interaction of Aza with chloroquine or 
hydroxychloroquine showed to be synergistic in only the MDA-MB-231 breast cancer cell 
line.  The uncloned early passage MCF-7 (ER+) breast cancer cell line was not sensitized 
significantly to the antiproliferative effects of the combination of Aza with the quinolines 
using clonogenic survival as the endpoint; however, using the MTS metabolism assay, the 
combination of Aza with CQ or HCQ did sensitize clonal ER- and ER+ MCF-7 cell lines to 
growth inhibition indicating that the response was not dictated by ER expression.  However, 
a growing body of evidence suggest that ER- cells, such as the MDA-MB-231 cells, which 
have a hypermethylated estrogen receptor gene promoter, are more sensitive than ER+ cells 
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to the effects of Aza (Ferguson et al., 1997; Yang et al., 2001; Worm et al., 2001)    Since 
the clonogenic survival assays are more sensitive and reliable than the MTS assay, the 
results support the hypothesis that combination of Aza with chloroquine or 
hydroxychloroquine would augment the antiproliferative effects of the antitumor quinolines, 
but only in the MDA-MB-231 cell line and not in the MCF-7 cell line.  Aza in combination 
with hydroxychloroquine showed to have the most promise in decreasing tumor cell survival 
in the MDA-MB-231 cell line.  Clonogenic survival was also assayed in the MCF-10A 
normal epithelial cells (n=2); however, these cells did not form discrete colonies (≥20 cells = 
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       0.433* 
 
       0.606* 
 
       CQ 
 
       0.317* 
 
       0.564* 
 
       HCQ 
 
       0.210*,a 
 
       0.334*,a,b 
 
       Aza + CQ 
 
       0.182*,a,b 
 
       0.436*,a 
 
       Aza + HCQ 
 
       0.094*,a,b,c 
 
       0.322*,a,b 
 
 
Table 3.  Tumor clonogenic survival using 5-Aza-dC.  MDA-MB-231 or MCF-7 cells 
(2x105/35 mm2 dish) were plated and allowed to attach for 3 hours before 5-Aza-dC (Aza, 
1µM) addition. Cells were incubated in the presence of solvent (control, DMSO) or MCF-7 
IC50 levels of chloroquine (CQ, 33µM) or hydroxychloroquine (HCQ, 57µM) 24 hours later.  
MDA-MB-231 and MCF-7 cells were harvested on days 3 and 4, respectively, and replated 
at a cloning cell density of 6x103 cells/60 mm2 dishes in 5ml DMEM/10% FBS and 
subjected to an undisturbed incubation period (5 or 7 days, respectively).  Colonies were 
visualized by staining the dishes with 3 ml of 0.5% crystal violet, 5% formalin, 50% ethanol, 
0.85% NaCl for 3 minutes, then rinsing with tap water.  Colonies were scored using a Nikon 
Eclipse TS100 microscope at 20X magnification with ≥20 MCF-7 cells and ≥50 MDA-MB-
231 cells =1 colony.  The data are represented as clonogenic fractions, where the clonogenic 
fraction of the control groups was set to equal 1.  Data are the mean of 3 independent 
experiments performed in duplicates. 
  
*  Statistically significant differences from the control (p<0.05). 
a  Statistically significant differences from Aza alone (p<0.05). 
b  Statistically significant differences from CQ alone (p<0.05). 
c  Statistically significant differences from HCQ alone (p<0.05). 
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2.3  Combination of Chloroquine or Hydroxychloroquine with 5-AzadC caused  
enhanced accumulation of cytoplasmic lipid droplets in MCF-7 and MDA-MB-231 
breast cancer cells.  The data presented above showed that the combination of chloroquine 
or hydroxychloroquine with Aza reduced cell and clonogenic survival in MDA-MB-231 
human breast cancer cells more than either quinoline alone.  Therefore, it was necessary to 
determine whether Aza in combination with chloroquine or hydroxychloroquine was also 
capable of augmenting the differentiation response.  Cellular differentiation was still 
assessed in the MCF-7 cells even though combination treatment did not sensitize them to an 
enhanced inhibition of clonogenic survival.  As evidence of cellular differentiation, 
combination treatment with 1µM Aza led to a modest accumulation of cytoplasmic lipid 
droplets detected by Oil Red-O staining in both the MDA-MB-231 and MCF-7 breast cancer 
cell lines after 48 hours of treatment (Figure 15).  The differentiation response was greater 
than either chloroquine or hydroxychloroquine alone at both the IC25 and IC50 levels.   
 MDA-MB-231 cells treated with chloroquine alone at IC25 and IC50 showed a 76% 
and 90% increase in lipid droplets, respectively, compared with 90% and 97% increase in 
cells pretreated with Aza.  Hydroxychloroquine alone showed an 84% and 87% increase in 
lipid droplets at its MDA-MB-231 IC25 and IC50 values, respectively, compared with 93% 
and 96% increase in cells pretreated with Aza.   
MCF-7 cells treated with chloroquine alone at IC25 and IC50 showed a 81% and 83% 
increase in lipid droplets, respectively, compared with 85% and 88% increase in cells 
pretreated with Aza, while hydroxychloroquine alone showed a 71% and 80% increase in 
lipid droplets at IC25 and IC50 values, respectively, compared with 85% and 92% increase in 
cells pretreated with Aza.  
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In summary, these experiments provide evidence that the differentiation response by 
the antitumor quinolines, chloroquine or hydroxychloroquine, can be modestly enhanced 
with pretreatment with 1µM Aza.  Pretreatment of MDA-MB-231 or MCF-7 breast cancer 
cells with Aza in combination with treatment with the IC25 values of either chloroquine or 
hydroxychloroquine, showed a greater percentage of ORO positive cells than either of the 
quinolines alone at their respective IC50 values.  Therefore, combination therapy with 1µM 
Aza seems to lower the concentration of chloroquine or hydroxychloroquine needed to 





















Figure 15.  Oil-Red-O (ORO) Histochemistry: Enhanced accumulation of cytoplasmic 
lipid droplets in MCF-7 and MDA-MB-231 breast cancer cells using Chloroquine or 
Hydroxychloroquine in combination with 5-Aza-dC.  A.) MDA-MB-231 (1x105 cells /35 
mm2 dish) were plated and treated with 1µM 5-Aza-dC (Aza).  24 hours later, cells were 
treated with solvent (control, DMSO) or hydroxychloroquine (HCQ, IC25=12µM) for 
another 24 hours and then stained with the ORO stain (red dots in the cytoplasm) and 
counterstained with the Mayer’s hematoxylin stain (blue nuclei).  B.) MCF-7 and MDA-
MB-231 cells were plated on 5x5 mm2 95% ethanol-washed glass coverslips in 35 mm2 
dishes at 2x105 and 1x105 cells per dish, respectively.  Cells were pretreated with 1µM Aza 
for 24 hours and then treated with chloroquine (CQ) or hydroxychloroquine (HCQ) at their 
respective IC50 and IC25 values for another 24 hours.  The ORO assay was performed and 
lipid droplet accumulation in the cytoplasm was visualized by light microscopy.  At least 
300 cells were counted visually.  Data represents the mean of 2 independent experiments 
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2.4  Combination of Chloroquine or Hydroxychloroquine with 5-Aza-dC elevated the 
Ki67 index.  To further test for differentiation, the G0 cell population in the breast cancer 
cell lines was measured using the Ki67 index.  The Ki67 index offers more reliability and 
biological relevance in the assessment of cellular differentiation compared with lipid droplet 
accumulation.  Ki67 protein was measured in both MCF-7 and MDA-MB-231 breast cancer 
cells after pretreatment with 1µM Aza and 24 hours of treatment with chloroquine or 
hydroxychloroquine at IC25 and IC50 MTS values (Figure 16).  The results showed that the 
combination of Aza with either chloroquine or hydroxychloroquine elevated the Ki67 index 
the most in the MDA-MB-231 breast cancer cells compared with the MCF-7 cells.  The 
differentiation response was greater than either chloroquine or hydroxychloroquine alone at 
both the IC25 and IC50 levels.   
MDA-MB-231 cells treated with chloroquine alone at IC25 and IC50 showed a Ki67 
index of 8.5 and 11.0, respectively, compared with an increased Ki67 index of 13.0 and 15.3 
in cells pretreated with ATRA.  Hydroxychloroquine alone showed a Ki67 index of 7.8 and 
9.5 at its MDA-MB-231 IC25 and IC50 values, respectively, compared with an increased 
Ki67 index of 12.1 and 14.3 in cells pretreated with ATRA.   
MCF-7 cells treated with chloroquine alone at IC25 and IC50 showed a Ki67 index of 
6.2 and 8.1, respectively, compared with an increased Ki67 index of 6.7 and 8.7 in cells 
pretreated with Aza, while hydroxychloroquine alone showed a Ki67 index of 5.8 and 5.5 at 
IC25 and IC50 values, respectively, compared with an increased Ki67 index of 6.2 and 7.4 in 
cells pretreated with Aza.  
These experiments provide evidence in support of the hypothesis that the 
differentiation response measured by increase in the G0 cell population can be augmented 
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with pretreatment with 1µM Aza more than either chloroquine or hydroxychloroquine alone.  
The differentiation response was more pronounced in the MDA-MB-231 cells versus the 
MCF-7 cells.  These results along with the tumor cell clonogenic survival data suggest that 
the combination of Aza with either chloroquine or hydroxychloroquine sensitized the MDA-
MB-231 (ER-) cells more than the MCF-7 (ER+) cells to growth inhibition and 
differentiation.  MDA-MB-231 cells were used in subsequent experiments to assess histone 






















Figure 16.  KI67 Histochemistry: Increased G0 cell population in both MCF-7 and 
MDA-MB-231 breast cancer cells treated with Chloroquine or Hydroxychloroquine in 
combination with 5-Aza-dC.  A.) MCF-7 (2x105 cells /35 mm2 dish) were pretreated with 
1µM 5-Aza-dC 24 hours prior to treatment with solvent (control, DMSO) or 
hydroxychloroquine (HCQ, IC25=30µM) ± (Aza).  24 hours later, Ki67 immunoreactivity 
was assayed.  Brown staining indicates the presence of Ki67 protein and cycling cells.  Blue 
staining indicates Ki67 negative or G0 cells.  B.) MCF-7 and MDA-MB-231 cells were 
plated on 5x5 mm2 95% ethanol-washed glass coverslips in 35 mm2 dishes at 2x105 and 
1x105 cells per dish, respectively.  Cells were pretreated with 1µM 5-Aza-dC 24 hours 
before addition of chloroquine (CQ) or hydroxychloroquine (HCQ) at their respective IC50 
and IC25 values.  24 hours later, Ki67 immunoreactivity was assayed.  KI67 negative 
percentage of the cell population was determined by visual counting. At least 500 cells were 
counted. (KI67 Index= % KI67 negative cells in drug treatment / % KI67 negative cells in 
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Chapter 3.  Histone H3/H4 Hyperacetylation Status in Response to Combination 
Treatment with Antitumor Quinolines 
 
3.1  Effect of combination treatment of Chloroquine or Hydroxychloroquine with 5-
Aza-dC on acetylated histone H4, HDAC, and RARβ2 protein levels in MDA-MB-231 
breast cancer cells.  The central goal of these studies was to explore whether a drug 
combination modulating epigenetic events would sensitize breast cancer cells to the 
antitumor activity of chloroquine or hydroxychloroquine.  To test whether pretreatment with 
5-Aza-dC (Aza) would alter the acetylation status of histones due to hypomethylation, 
western blot analyses were conducted to evaluate acetylated histone H4 and HDAC protein 
levels.  RARβ2 protein levels were also assessed since it has been suggested that methylation 
may be responsible for the lack of RARβ2 gene expression in cancer cell lines (Yang et al., 
2002).  Histone proteins were extracted from MDA-MB-231 cells pretreated with 1µM Aza 
for 24 hours prior to chloroquine or hydroxychloroquine addition for different time points 
(Figure 17).  Trichostatin A (TSA) was used as a positive control for HDAC inhibition and 
histone hyperacetylation.   
By 4 hours after chloroquine addition, there was a 56% reduction in HDAC protein 
levels in cells that were pretreated with Aza compared with a 40% reduction in cells with no 
pretreatment and only chloroquine addition.  Also by 4 hours after chloroquine treatment, 
there was significant induction of histone hyperacetylation with a 6.6 fold increase in 
acetylated histone H4 protein in cells pretreated with Aza compared to cells with solvent 
alone.  By 8 hours after chloroquine treatment, there was a significant 4.4 fold increase in 
RARβ2 protein in cells pretreated with Aza and this increase was sustained even at 24 hours.  
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By 4 hours after hydroxychloroquine addition, there was a 42% reduction in HDAC 
protein levels in cells that were pretreated with Aza compared with a 37% reduction in cells 
with no pretreatment and only hydroxychloroquine addition.  Also by 4 hours after 
hydroxychloroquine treatment, there was significant induction of histone hyperacetylation 
with a 4.5 fold increase in acetylated histone H4 protein in cells pretreated with Aza 
compared to cells with solvent alone.  There was a maximum increase in RARβ2 protein 
levels in cells pretreated with Aza by 12 hours after hydroxychloroquine treatment.  
Increased RARβ2 protein levels were sustained even at 24 hours.   
These results support the hypothesis that combination of Aza with chloroquine or 
hydroxychloroquine would increase histone H4 acetylation status via inhibition of HDAC 
protein and therefore, increase RARβ2 tumor suppressor protein levels.  These results 
combined with cell survival and differentiation assays, suggest that Aza in combination with 
either chloroquine or hydroxychloroquine are promising agents for the generation of safer 
















Figure 17.  HDAC, acetylated histone H4, and RARβ2 protein levels in MDA-MB-231 
cells following treatment with Chloroquine or Hydroxychloroquine ± Aza.   2x106 or 
6x108 MDA-MB-231 cells were allowed to attach for 3 hours prior to treatment with 1µM 
Aza for whole cell or histone extraction, respectively.  24 hours after Aza addition, cells 
were treated with control (DMSO), trichostatin A (TSA, 300nM), chloroquine (CQ, 
IC50=11µM), or hydroxychloroquine (HCQ, IC50=28µM).  At 0.5, 4, 8, 12, and 24 hours 
after TSA and quinoline treatment, either whole cell lysates were prepared or total histone 
proteins were isolated using acid-extraction.  80µg of proteins from whole cell lysates or 
20µg of purified histone proteins were resolved on a 10% or 15% acrylamide gel, 
respectively, and analyzed by Western blot.  Signals were quantitated by FluoroChem 
(Alpha Innotech, San Leandro, CA) spot densitometry using automatic background 
subtraction.  Statistically significant differences from the control in three independent 
experiments are indicated (p<0.05). 
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3.2  Effect of combination treatment of Chloroquine or Hydroxychloroquine with 
ATRA on acetylated histone H3/H4, HDAC, and RARβ2 protein levels in MCF-7 
breast cancer cells.  The central goal of these studies was to test whether a drug 
combination modulating epigenetic events would sensitize breast cancer cells to the 
antitumor activity of chloroquine or hydroxychloroquine.  To examine whether pretreatment 
with ATRA would alter the acetylation status of histones, western blot analyses were 
conducted to assess acetylated histone H4 and HDAC protein levels.  The RARβ2 gene is 
silenced in human carcinoma cells.  Since growing evidence suggests that retinoids exert 
their chemopreventive effects by RARβ2 induction (Lotan et al., 1995; Yang et al., 2002), 
RARβ2 protein levels were also assessed.  Whole cell lysates or histone proteins were 
extracted from MCF-7 cells pretreated with 1µM ATRA for 24 hours prior to chloroquine or 
hydroxychloroquine addition for different time points (Figure 18).  Trichostatin A (TSA) 
was used as a positive control for HDAC inhibition and histone hyperacetylation.   
By 4 hours after chloroquine addition, there was a 33%, 33%, and 36% reduction in 
HDAC protein levels in cells that were pretreated with 1, 10, or 100 µM ATRA, 
respectively, compared with a 27% reduction in cells with no pretreatment and only 
chloroquine addition.  By 8 hours after chloroquine treatment, there was a significant 
induction of histone hyperacetylation with a 3.9 fold increase in acetylated histone H4 
protein and a 3.4 fold increase in acetylated histone H3 protein in cells pretreated with 
100µM ATRA compared to cells with solvent alone.  There was a pronounced histone H3 
hyperacetylation response even by 0.5hr in cells pretreated with 1µM ATRA and increased 
levels were sustained even at 12 hours. By 12 hours after chloroquine treatment, there was a 
significant induction of RARβ2 protein levels in cells pretreated with Aza and this increase 
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was sustained even at 24 hours.  Cells pretreated with 1µM ATRA showed the greatest 
increase in RARβ2 protein levels. 
By 4 hours after hydroxychloroquine addition, there was a 35%, 31%, and 41% 
reduction in HDAC protein levels in cells that were pretreated with 1, 10, or 100 µM ATRA, 
respectively, compared with a 30% reduction in cells with no pretreatment and only 
hydroxychloroquine addition.  By 8 hours after hydroxychloroquine treatment, there was a 
significant induction of histone hyperacetylation with a 4.2 fold increase in acetylated 
histone H4 protein and a 5.6 fold increase in acetylated histone H3 protein in cells pretreated 
with 100µM ATRA compared to cells with solvent alone.  By 12 hours after 
hydroxychloroquine treatment, there was a significant induction of RARβ2 protein levels in 
cells pretreated with ATRA and this increase was sustained even at 24 hours.  Cells 
pretreated with 1µM ATRA showed the greatest increase in RARβ2 protein levels. 
These results support the hypothesis that combination of ATRA with chloroquine or 
hydroxychloroquine would increase histone H4 acetylation status via inhibition of HDAC 
protein and therefore, increase RARβ2 tumor suppressor protein levels.  These results 
combined with cell survival and differentiation assays, suggest that ATRA in combination 
with either chloroquine or hydroxychloroquine are promising agents for the generation of 
safer and less toxic chemotherapeutic agents for the prevention and treatment of both ER- 











Figure 18.  HDAC, acetylated histone H3/H4, and RARβ2 protein levels in MCF-7 cells 
following treatment with Chloroquine or Hydroxychloroquine ± ATRA.   2x106 or 
1x107 MCF-7 cells were allowed to attach for 3 hours prior to treatment with 1, 10, or 
100µM ATRA for whole cell or histone extraction, respectively.  24 hours after ATRA 
addition, cells were treated with control (DMSO), trichostatin A (TSA, 300nM), chloroquine 
(CQ, IC50=33µM), or hydroxychloroquine (HCQ, IC50=57µM).  At 0.5, 4, 8, 12, and 24 
hours after TSA and antimalarial treatment, either whole cell lysates were prepared or total 
histone proteins were isolated using acid-extraction.  80µg of proteins from whole cell 
lysates or 20µg of purified histone proteins were resolved on a 10% or 15% acrylamide gel, 
respectively, and analyzed by Western blot.  Signals were quantitated by FluoroChem 
(Alpha Innotech, San Leandro, CA) spot densitometry using automatic background 
subtraction.  Statistically significant differences from the control in three independent 
experiments are indicated (p<0.05). 
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3.3  Histone Deacetylase (HDAC) Activity of Chloroquine or Hydroxychloroquine ± 
ATRA.  To examine whether the HDAC protein levels observed in the Western blotting 
experiments (Figure 18) were directly or indirectly inhibited by chloroquine or 
hydroxchloroquine ± pretreatment with ATRA, HDAC fluorescent activity was measured 
(Figure 19).  This assay system measures histone deacetylase activity present in a 
commercial HeLa (human cervical cancer cell line) cell nuclear extract, which is rich in 
HDAC activity.  The HDAC substrate contains an acetylated Lysine side chain.  Upon 
incubation of the substrate with the HeLa nuclear extract, HDAC-mediated deacetylation 
sensitizes the substrate so that it becomes a fluorophore with addition of a developer.   
 The potent HDAC inhibitor, TSA, was used as a positive control.  To our surprise, 
1µM ATRA alone showed a statistically significant inhibitory effect on HDAC activity.  
Direct inhibition of HDAC activity by ATRA was sustained, but not decreased further upon 
combination treatment with either chloroquine or hydroxychloroquine.  As a control, ATRA 
was added after the developer to make certain that the decrease in fluorescence intensity was 
not due to ATRA quenching fluorescence (Sundaram et al., 1998), but rather due to its direct 
inhibition of the HDAC enzyme.  HDAC inhibition might contribute to both MCF-7 and 
MDA-MB-231 cell differentiation in response to ATRA, but not to the differentiation 
quinolines.  To date, there are no other publications showing that ATRA acts as a direct 
HDAC inhibitor.   Therefore, ATRA might exert its therapeutic effects as a differentiation 
agent by modulating HDAC enzyme activity.   
  The results from the HDAC activity assay combined with cell survival and 
differentiation assays, suggest that ATRA in combination with either chloroquine or 
hydroxychloroquine are promising agents for the generation of safer and less toxic 
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chemotherapeutic agents for the prevention and treatment of both ER- and ER+ breast 
cancers.  To understand the role of either chloroquine or hydroxychloroquine alone and with 
ATRA on histone acetylation status, mass spectrometry needed to be used to generate a 
profile on the level and site of histone acetylation upon treatment with the most promising 
combination of agents.   Since ATRA in combination with HCQ had the most significant 
inhibitory effect on clonogenic survival, and since clonogenic survival is the most sensitive 
test for predicting the responsiveness of a tumor to clinical treatment, the combination of 
ATRA with HCQ was assessed subsequently by mass spectrometry to measure its effect on 

































































































































Figure 19.  Histone Deacetylase (HDAC) Fluorescent Activity of Chloroquine or 
Hydroxychloroquine ± ATRA.  Drugs were screened for the ability to directly inhibit 
histone deacetylase (HDAC) activity in HeLa cell nuclear extracts using the HDAC 
Fluorescent Activity Assay.  TSA (35nM) was used as a positive control.  Chloroquine 
(MCF-7 IC50=33µM) or hydroxychloroquine (MCF-7 IC50=57µM ) ± 1µM ATRA were 
tested for HDAC activity.  Data are the mean of n=3 experiments ± SEM performed in 
triplicates per treatment.  Statistically significant differences from the control are indicated 
(*p<0.05). 
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3.4  Identification of acetylated histone H3 by mass spectrometry.  Since an 8 hour 
treatment with HCQ displayed the greatest overall histone acetylation profile (Figure 18), 
histone H3 samples at this time-point were resolved by SDS-PAGE and visualized using 
Coomassie Blue staining.  The histone H3 band was excised and digested with the 
endoprotease, trypsin.  The resulting tryptic peptides were analyzed by mass spectrometry to 
determine their individual mass values.  Mass values for the specific peptide sequences of 
the N-terminal portion of histone H3 were attained by matching the measured masses with 
expected calculated mass values acquired from the International Protein Index (IPI) human 
database using Sequest Software.  Acetylation sites were identified using a differential 
modification of 42 Daltons added to Lysine residues.  Peptide sequences of histone H3 
showed 13 possible acetylation sites at Lys(K)-4, 9, 14, 18, 23, 27, 36, 37, 56, 64, 79, 115, 
and 122 (Figure 20A). 
Control cells treated with solvent (DMSO) only, displayed acetylated Lysine 
residues at all possible sites except for K4 and K9 of the N-terminal tail.  Cells treated with 
hydroxychloroquine only showed acetylated Lysine residues at all possible sites except for 
K4; however, cells pretreated with 1µM ATRA before hydroxychloroquine addition 
displayed acetylated Lysine residues at all possible sites including K4.  Cells treated with 
only TSA (positive control) also were acetylated at all possible Lysine sites.  These results 
were consistent with the hypothesis of a “zip” model for histone H4, whereby acetylation 
proceeds from the direction of the nucleosome towards the N-terminal tail Lysine residues, 
and deacetylation proceeds in the reverse direction (Zhang et al., 2002). 
 A representative MS/MS peptide sequence from each treatment group is also shown 
(Figure 20B-E) to depict acetylation at lysine sites on the N-terminal tail of histone H3.  The 
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MS/MS spectra generated is the result of fragmentation of peptides that primarily occur at 
the amide bond (-CO-NH-) between two amino acid residues. The most commonly observed 
fragmentation ions are b and y ions. B ions are sequence-specific fragment ions derived 
from the N-terminus and y ions are from the C-terminus.  Attempts were made to quantitate 
these peptide sequences in order to measure global acetylation levels.  However, because the 
N-terminal tail is more basic, there is a possibility of attaining a higher charge ratio, which 
would lead to a more complex fragmentation pattern and high background noise level and 
thereby, decrease the level of confidence in the identification of the peptide sequence.  In 
order to increase the level of confidence, an in-solution protein purification using HPLC, 
rather than an in-gel tryptic digest, would be the preferred method-of-choice because it 
would increase the recovery of peptide sequences with lower charge ratios.  Nevertheless, 
the data from the peptide sequences provide a working-model, consistent with the Zhang’s 

















Figure 20.  Histone H3 acetylation status in MCF-7 cells.  A.) 1x107 MCF-7 cells were 
either pretreated with 1µM ATRA or not for 24 hours.  Cells were then treated with solvent 
(DMSO; control), trichostatin A (TSA, 300nM), or hydroxychloroquine (CQ, IC50=57µM) 
for 8 hours.  Total histone proteins were isolated using acid-extraction protocol from 
Upstate.  20µg of purified histone proteins were resolved on a 15% acrylamide gel and 
confirmed by Coomassie Blue staining.  Histone H3 bands were excised, trypsin digested, 
and separated using reverse-phase HPLC with C18 column.  Samples were analyzed on a 
ThermoFinnigan LCQ Deca XP Plus ion trap.  MS/MS spectra were searched against 
International Protein Index (IPI) human database using Sequest Software.  Acetylation sites 
were identified using a differential modification of 42 Daltons added to Lysine residues in 
two independent experiments.  B-E.)  MS/MS spectra of a histone H3 peptide sequence in 
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B.  Control (DMSO) 
 
Seq # b y (+1)  Seq # b y (+1) 
A 1 72 1531.9 14  R 8 913.5 775.4 7 
R 2 228.1 1460.8 13  K 9 1041.6 619.3 6 
T 3 329.2 1304.7 12  S 10 1128.7 491.2 5 
K 4 457.3 1203.7 11  T 11 1229.7 404.2 4 
Q 5 585.3 1075.6 10  G 12 1286.7 303.2 3 
T 6 686.4 947.5 9  G 13 1343.8 246.1 2 











C.  Hydroxychloroquine 
 
Seq # b y (+1)  Seq # b y (+1) 
A 1 72 2651.5 23  G 13 1385.8 1323.7 11 
R 2 228.1 2580.4 22  *K 14 1555.8 1266.7 10 
T 3 329.2 2424.3 21  A 15 1626.9 1096.6 9 
K 4 457.3 2323.3 20  P 16 1723.9 1025.6 8 
Q 5 585.3 2195.2 19  R 17 1880.0 928.5 7 
T 6 686.4 2067.1 18  *K 18 2050.1 772.4 6 
A 7 757.4 1966.1 17  Q 19 2178.2 602.3 5 
R 8 913.5 1895 16  L 20 2291.3 474.3 4 
*K 9 1083.6 1738.9 15  A 21 2362.3 361.2 3 
S 10 1170.7 1568.8 14  T 22 2463.4 290.2 2 
T 11 1271.7 1481.8 13  *K 23 2633.5 189.1 1 







D. ATRA + Hydroxychloroquine 
 
Seq # b y (+1)  Seq # b y (+1) 
A 1 72 2110.1 18  S 10 1212.7 985.5 9 
R 2 228.1 2039.1 17  T 11 1313.7 898.5 8 
T 3 329.2 1883.0 16  G 12 1370.7 797.4 7 
*K 4 499.3 1782.0 15  G 13 1427.8 740.4 6 
Q 5 627.3 1611.9 14  *K 14 1597.8 683.4 5 
T 6 728.4 1483.8 13  A 15 1668.9 513.3 4 
A 7 799.4 1382.8 12  P 16 1765.9 442.3 3 
R 8 955.5 1311.7 11  R 17 1922 345.2 2 











E.  Trichostatin A (TSA) 
 
Seq # b y (+1)  Seq # b y (+1) 
A 1 72 2693.5 23  G 13 1427.8 1323.7 11 
R 2 228.1 2622.4 22  *K 14 1597.8 1266.7 10 
T 3 329.2 2466.3 21  A 15 1668.9 1096.6 9 
*K 4 499.3 2365.3 20  P 16 176.5.9 1025.6 8 
Q 5 627.3 2195.2 19  R 17 1922 928.5 7 
T 6 728.4 2067.1 18  *K 18 2092.1 772.4 6 
A 7 799.4 1966.1 17  Q 19 2220.2 602.3 5 
R 8 955.5 1895 16  L 20 2333.3 474.3 4 
*K 9 1125.6 1738.9 15  A 21 2404.3 361.2 3 
S 10 1212.7 1568.8 14  T 22 2505.4 290.2 2 
T 11 1313.7 1481.8 13  *K 23 2675.5 189.1 1 






     































3.5  Identification of acetylated histone H4 by mass spectrometry.  Histone H4 samples 
were also resolved by SDS-PAGE and visualized using Coomassie Blue staining.  The 
histone H4 band was excised and digested with trypsin.  The resulting tryptic peptides were 
analyzed by mass spectrometry to determine their individual mass values.  Mass values for 
the specific peptide sequences of the N-terminal portion of histone H4 were attained by 
matching the measured masses with expected calculated mass values acquired from the 
International Protein Index (IPI) human database.  Acetylation sites were identified using a 
differential modification of 42 Daltons added to Lysine residues.  The acetylation sites for 
histone H4 were established showing 11 possible acetylation sites at Lys(K)-5, 8, 12, 16, 20, 
31, 44, 59, 77, 79, and 91 (Figure 21A). 
Control cells treated with solvent (DMSO), displayed acetylated Lysine residues at 
all possible sites except for K5, K8, and K12.  Cells treated with hydroxychloroquine only 
showed acetylated Lysine residues at all possible sites except for K5 and K8.  Interestingly, 
cells with only TSA treatment (positive control) and cells pretreated with 1µM ATRA 
before hydroxychloroquine addition displayed acetylated Lysine residues at all possible 
sites.  These results were once again consistent with the hypothesis of a “zip” model, 
whereby acetylation of histone H4 proceeds in the direction from the nucleosome towards 
the N-terminal tail lysine residues, and deacetylation proceeds in the reverse direction 
(Zhang et al., 2002).  In summary, hydroxychloroquine alone showed modification at K12 
sites compared to control cells.  The remaining acetylation sites, K5 and K8 were modified 
when cells were pretreated with 1µM ATRA.   
The site of acetylation on the N-terminal tail of histone H4 was generated by 
fragmentation of a peptide sequence from each treatment group (Figure 21B-E).  Although 
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attempts at quantitation were unsuccessful using the in-gel tryptic digest to measure global 
acetylation levels in both histone H3 and histone H4, an in-solution protein purification 
using HPLC would be a more promising alternative for increasing the recovery of peptide 
sequences with lower charge ratios, and thus increasing the confidence of peptide 
identification.  Nevertheless, the data from the peptide sequences provide a working-model, 
consistent with the Zhang’s “zip” model for acetylation.  Using this model, the overall data 
suggest that hydroxychloroquine may exert its effects by instead regulating acetylation via 
histone acetyltransferase (HAT) either directly or indirectly since both histone H3 and 
histone H4 lysine sites were modified in the direction of acetylation, but not all lysine sites 
were acetylated because histone deacetylase (HDAC) was not completely inhibited by 
hydroxychloroquine alone.  On the other hand, since ATRA has been identified as a direct 
HDAC inhibitor, the model would explain why all the N-terminal lysine sites of histones H3 

















Figure 21.  Histone H4 acetylation status in MCF-7 cells.  A.) 1x107 MCF-7 cells were 
either pretreated with 1µM ATRA or not for 24 hours.  Cells were then treated with solvent 
(DMSO; control), trichostatin A (TSA, 300nM), or hydroxychloroquine (HCQ, IC50=57µM) 
for 8 hours.  Total histone proteins were isolated using acid-extraction protocol from 
Upstate.  20µg of purified histone proteins were resolved on a 15% acrylamide gel and 
confirmed by Coomassie Blue staining.  Histone H4 bands were excised, trypsin digested, 
and separated using reverse-phase HPLC with C18 column.  Samples were analyzed on a 
ThermoFinnigan LCQ Deca XP Plus ion trap.  MS/MS spectra were searched against 
International Protein Index (IPI) human database using Sequest Software.  Acetylation sites 
were identified using a differential modification of 42 Daltons added to Lysine residues in 
two independent experiments.  B-E.)  MS/MS spectra of a histone H4 peptide sequence in 








SGRGKGGKGL   GKGGAKRHRK VLRDNIQGIT   KPAIRRLARR   GGVKRISGLI 
YEETRGVLKV   FLENVIRDAV   TYTEHAKRKT   VTAMDVVYAL   KRQGRTLYGF   GG
5 8 12 16 20 31 44
59 77 79 91
SGRGKGGKGL   GKGGAKRHRK VLRDNIQGIT   KPAIRRLARR   GGVKRISGLI 
YEETRGVLKV   FLENVIRDAV   TYTEHAKRKT   VTAMDVVYAL   KRQGRTLYGF   GG
16 20 31 44
59 77 79 91
SGRGKGGKGL   GKGGAKRHRK VLRDNIQGIT   KPAIRRLARR   GGVKRISGLI 
YEETRGVLKV   FLENVIRDAV   TYTEHAKRKT   VTAMDVVYAL   KRQGRTLYGF   GG
12 16 20 31 44
59 77 79 91
SGRGKGGKGL   GKGGAKRHRK VLRDNIQGIT   KPAIRRLARR   GGVKRISGLI 
YEETRGVLKV   FLENVIRDAV   TYTEHAKRKT   VTAMDVVYAL   KRQGRTLYGF   GG
5 8 12 16 20 31 44
59 77 79 91
SGRGKGGKGL   GKGGAKRHRK VLRDNIQGIT   KPAIRRLARR   GGVKRISGLI 
YEETRGVLKV   FLENVIRDAV   TYTEHAKRKT   VTAMDVVYAL   KRQGRTLYGF   GG
5 8 12 16 20 31 44
59 77 79 91
A. 
 






















B. Control (DMSO) 
 
Seq # b y (+1)  Seq # b y (+1) 
S 1 88.0 2444.4 23  G 13 1140.7 1361.8 11 
G 2 145.1 2357.4 22  G 14 1197.7 1304.8 10 
R 3 301.2 2300.4 21  A 15 1268.7 1247.8 9 
G 4 358.2 2144.3 20  *K 16 1438.8 1176.7 8 
K 5 486.3 2087.3 19  R 17 1594.9 1006.6 7 
G 6 543.3 1959.2 18  H 18 1732.0 859.5 6 
G 7 600.3 1902.1 17  R 19 1888.1 713.5 5 
K 8 728.4 1845.1 16  *K 20 2058.2 557.4 4 
G 9 785.4 1717.0 15  V 21 2157.2 387.3 3 
L 10 898.5 1660.0 14  L 22 2270.3 266.2 2 
G 11 955.5 1546.9 13  R 23 2826.4 175.1 1 




     






Seq # b y (+1)  Seq # b y (+1) 
S 1 88.0 1948.1 19  G 11 955.5 1050.6 9 
G 2 145.1 1861.1 18  *K 12 1125.6 993.5 8 
R 3 301.2 1804.0 17  G 13 1182.7 823.5 7 
G 4 358.2 1647.9 16  G 14 1239.7 766.4 6 
K 5 486.3 1590.9 15  A 15 1310.7 709.4 5 
G 6 543.3 1462.8 14  *K 16 1480.8 638.4 4 
G 7 600.3 1405.8 13  R 17 1636.9 468.3 3 
K 8 728.4 1348.8 12  H 18 1774.0 312.2 2 
G 9 785.4 1220.7 11  R 19 1930.1 175.1 1 










D. ATRA + Hydroxychloroquine 
     
Seq # b y (+1)  Seq # b y (+1) 
S 1 88.0 2032.1 19  G 11 1039.5 1050.6 9 
G 2 145.1 1945.1 18  *K 12 1209.6 993.5 8 
R 3 301.2 1888.0 17  G 13 1266.7 823.5 7 
G 4 358.2 1731.9 16  G 14 1323.7 766.4 6 
*K 5 528.3 1674.9 15  A 15 1394.7 709.4 5 
G 6 585.3 1504.8 14  *K 16 1564.8 638.4 4 
G 7 642.3 1447.8 13  R 17 1720.9 468.3 3 
*K 8 812.4 1390.8 12  H 18 1858.0 312.2 2 
G 9 869.4 1220.7 11  R 19 2014.1 175.1 1 
L 10 982.5 1163.7 10       








E. Trichostatin A (TSA) 
 
Seq # b y (+1)  Seq # b y (+1) 
S 1 88.0 2570.4 23  G 13 1266.7 1361.8 11 
G 2 145.1 2463.4 22  G 14 1323.7 1304.8 10 
R 3 301.2 2426.4 21  A 15 1394.7 1247.8 9 
G 4 358.2 2270.3 20  *K 16 1564.8 1176.7 8 
*K 5 528.3 2213.3 19  R 17 1720.9 1006.6 7 
G 6 585.3 2043.2 18  H 18 1858.0 850.5 6 
G 7 642.3 1986.1 17  R 19 2014.1 713.5 5 
*K 8 812.4 1929.1 16  *K 20 2184.2 557.4 4 
G 9 869.4 1759.0 15  V 21 2283.2 387.3 3 
L 10 982.5 1702.0 14  L 22 2396.3 288.2 2 
G 11 1039.5 1588.9 13  R 23 2552.4 175.1 1 










     
   
m/z 
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3.6  Histone Acetylase (HAT) Activity of Hydroxychloroquine and ATRA.  A non-
radioactive ELISA assay containing PCAF as an active source of HAT enzyme was used to 
test whether the observed acetylation response is due to modulation of HAT activity (Figure 
22).  Interestingly, both ATRA and hydroxychloroquine caused direct HAT activation 
shown by increased acetylation of histone H3 and histone H4 substrate peptides.  
Hydroxychloroquine, augmented HAT activity more than ATRA alone; however, the 
combination of the drugs showed a more pronounced activation of HAT compared to basal 
levels.  The hypothesis was that HCQ acts via HAT activation.  The overall data suggest that 
direct HAT activation might contribute to both MCF-7 and MDA-MB-231 cell 
differentiation in response to the differentiation quinoline, hydroxychloroquine.  On the 
other hand, ATRA seems to display dual roles by activating HAT as well as directly 
inhibiting HDAC (Figure 19).  ATRA works thru the same mechanism of 
hydroxychloroquine by modulating HAT activity; therefore, an increase in HAT activity 
was seen upon combination treatment with both hydroxychloroquine and ATRA.  However, 
ATRA acts via an independent mechanism by inhibiting HDAC enzymatic activity.  
Thereby, enhanced antiproliferative, differentiation, and histone acetylation responses are 
achieved during combination therapy with ATRA rather than the differentiating quinoline 





































































































































































































Figure 22.  Histone Acetyltransferase (HAT) Activity of Hydroxychloroquine ± ATRA.  
Drugs were screened using an indirect ELISA Assay for the detection of acetyl residues on 
biotinylated Histone H3 or Histone H4 peptides using 75ng of recombinant PCAF, an active 
histone acetyltransferase enzyme, in the presence of 100µM Acetyl-CoA and HAT assay 
buffer.  Acetylated Histone H3 or Histone H4 peptides were used as positive controls.  
Hydroxychloroquine (MCF-7 IC50=57µM ) ± 1µM ATRA were tested for HAT activity.  
Data are the mean of n=3 experiments ± SEM performed in triplicates per treatment.  
Statistically significant differences from control (DMSO) are indicated (*p<0.05). 
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Chapter 4.  Additional Studies. 
 
In addition to the studies delineated in the previous three chapters, several other experiments 
were conducted in conjunction with other projects.  The results of these additional studies 
have been outlined and have either been published with the projects that they had supported 
or have aided in the understanding of future directions. 
 
4.1  Martirosyan, A.R., Rahim-Bata, R., Freeman, A.B., Clarke, C.D., Strobl, J.S.  (2004) 
Identification of differentiation-inducing quinolines as experimental breast cancer 
agents in the MCF-7 human breast cancer cell model.  Biochemical Pharmacology (in 
press). 
The rationale for these studies was to develop promising agents for cancer 
differentiation therapy by screening quinoline-ring containing compounds.  The National 
Service Center (NSC) compound library maintained by the Developmental Therapeutics 
Program of the National Cancer Institute (NCI) allowed us to perform an anticancer screen 
data search by substructure using the known structure of differentiating antimalarial drugs 
(http://dtp.nci.nih.gov./).  The NCI database screens compounds in a panel of cancer cells:  
breast, colon, lung, ovarian, renal, leukemia, melanoma, and CNS.  It contains > 45,000 
compounds with antiproliferative activity in human breast tumor cells; however, the 
mechanism of these compounds is unknown.  The most promising antiproliferative NSC 
anticancer agents with the structural match from the anticancer screen data search were 
provided by NCI and used in subsequent experiments as experimental agents in the MCF-7 




Figure 23.  Chemical structures of quinoline-ring containing NSC compounds.   
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4.1.1  Antiproliferative quinolines act as cell differentiation agents.  The differentiation 
response of only compounds with known antiproliferative activity and unknown mechanism 
of action against breast cancer in vitro was measured.  The antiproliferative activity of each 
compound in both the MCF-7 and MDA-MB-231 cell lines was reported using the MTS 
metabolism assay to attain IC50 values (Table 4).  Growth curves using the IC50 values for 
the drugs were generated to explore the antiproliferative effects of the quinoline compounds 
(Figure 24).  Functional screening assays were then performed to assess cell differentiation 
activity in the MCF-7 cell line using the MTS IC50 levels (Table 5)  Primary markers for 
cellular differentiation include changes in cellular morphology as characterized by the 
accumulation of cytoplasmic lipid droplets, and exit from the cell cycle as measured by loss 
of Ki67 protein.  Both of these endpoints were measured in all of the compounds as a screen 
for differentiation activity.  Next, the drugs were screened for the ability to directly inhibit 
histone deacetylase (HDAC) activity in Hela cell nuclear extracts using the HDAC 
Fluorescent Activity Assay.  Only NSC86371 and NSC3852 inhibited HDAC and caused 
cell differentiation.  However, none of the other quinoline compounds inhibited HDAC 












Table 4               MCF-7          MDA-MB-231 
NSC # Name MTS IC50     (µM) 
SRB GI50     
(µM) 
MTS IC50     
(µM) 
SRB GI50     
(µM) 
14050 Chloroquine 32.8 19 10.8 16 
4375 Hydroxychloroquine 56.6 nd 27.9 nd 
69603   14.4 0.9 0.9 0.6 
305819   7.9 13 3.9 9.4 
124637   13 14 34.4 17 
86371   5.7 nd 1.1 nd 
86373   12.9 nd 12.9 nd 
85700   6.5 7 nd 33.2 





Table 4.  Antiproliferative activity of breast tumor differentiating NSC quinoline 
compounds in MCF-7 and MDA-MB-231 cells.  MCF-7 and MDA-MB-231 breast cancer 
cells were plated at 4.0x103 and 5.0x102 cells per well in 96-well plates, respectively.  MTS 
IC50 growth inhibitory concentrations represent the inhibition of mitochondrial metabolism 
of MTS following a 48 hour exposure to each compound.  Data are the mean of n=3 
independent experiments performed with 10 concentrations of each compound in triplicate.  
























Figure 24.  Inhibition of MCF-7 cell growth by quinoline compounds.  MCF-7 cells 
(2x105/35 mm2 dish) were plated in 3ml of 5% FBS DMEM and allowed to attach for 3 
hours before drug addition. Following drug treatments (MTS IC50 values), cell counting and 
viability were assessed on the indicated days to generate the growth curves. Data represents 




























 # NSC # Name Oil Red-O     (µM)  Ki67 Index 
HDAC activity   
(% control) 
1 14050 Chloroquine 1 6.6 * 91 ± 6 
2 4375 Hydroxychloroquine 5 3.6 94 ± 1 
3 13453 Amodiaquin 10 2.4 86 ± 4 
4 10004 Quinidine 10 5 100 ± 13 
5 5362 Quinine 30 4.1 102 ± 14 
6 157387 Mefloquine Negative 0.3 90 ± 2 
7 305789 Halofantrine 5 1.4 81 ± 13 
8 149765 Primaquine 2.5 1.1 95 ± 14 
9   Quinoline Negative 0.4 96 ± 7 
10 2039   15 1.6 95 ± 4 
11 3852   10 7.2 * 69 ± 6 * 
12   Quinolinic Acid Negative 0.4 99 ± 6 
13 69603   1 6 * 111 ± 7 
14 305819   1 5.8 * 90 ± 17 
15 124637   1 3.4 127 ± 14 
16 4239   1.3 1.9 96 ± 4 
17 10010   3.5 8.3* 94 ± 8 
18 86371   1 6 * 65 ± 5 * 
19 86373   1 4.7 97 ± 2 
20 86372   2 0.8 91 ± 7 
21 85700   1 4.1 97 ± 1 
22 85701   0.5 2.7 90 ± 7 




Table 5.  Summary of differentiation activity by NSC compounds in MCF-7 breast 
cancer cells.  Functional screening assays for cell differentiation activity were performed 
using the compounds in bold.  The lowest concentration of each compound that produced an 
Oil Red-O response is shown.  Ki67 index, which is indicative of the fraction of G0 cells in 
a population, and inhibition of HDAC activity in vitro, which is expressed as a percent of 
HDAC activity in solvent control groups were determined after a 48 hour exposure to the 
IC50 levels of each compound.   Data are the mean ± SEM of atleast n=3 experiments 
performed in duplicates.  Statistically significant differences from the control are indicated 
(*p<0.05).  
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4.1.2  E2F-1 as a differentiation response marker.  The antiproliferative activity of each 
compound in both the MCF-7 and MDA-MB-231 cell lines was reported using the MTS 
metabolism assay as shown in Table 4.  Next, using the MTS IC50 values, expression of 
E2F-1 protein was assessed in MCF-7 breast cancer cells by Western blotting (Figure 25).  
The results showed that E2F-1 protein was downregulated by the quinoline compounds.   
Quinoline and primaquine served as negative controls since both failed to induce 
differentiation as measured by loss of Ki67 protein and lack of lipid droplet accumulation 
(quinoline only) (Table 5).  E2F-1 protein was unchanged in MCF-7 cells treated with either 
quinoline or primaquine.  Augmentation of the differentiation response was affirmed by 
downregulation of E2F-1 cell cycle regulatory protein.  These data suggest that E2F-1 
protein is an appropriate biochemical marker for in vitro activity in response to candidate 
quinoline differentiation agents. 
 Alterations in the level of E2F-1 and c-myc proteins were assessed in response to 24 
and 48 hours of treatment with the candidate quinoline differentiation agents (Figure 26 and 
27, respectively).  There was significant downregulation of both proteins by 48 hours of 
quinoline treatment.  NSC69603, quinidine, and hydroxychloroquine showed the greatest 




















































































































































































Figure 25.  E2F-1 protein expression in MCF-7 cells following treatment with quinoline 
compounds.  MCF-7 (2x106 cells/60 mm2 dish) were treated with quinidine (90µM) or 
NSC69603, hydroxychloroquine, NSC3852, NSC86371, chloroquine, NSC10010, 
NSC305819, quinoline, or primaquine at their respective IC50 concentrations for 48 hours.  
80µg of whole cell extract proteins were resolved on a 10% acrylamide gel and analyzed by 
Western blot.  Signals were quantitated by FluoroChem (Alpha Innotech, San Leandro, CA) 
spot densitometry using automatic background subtraction.  Data shown represents the mean 
of three experiments ±SEM or two experiments (denoted on the figure).  Statistically 
significant differences from the control are indicated (*p<0.05). 
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Figure 26.  Downregulation of E2F-1 protein in MCF-7 cells treated with quinoline 
compounds.  MCF-7 (2x106 cells/60 mm2 dish) were treated with quinidine (QD, 90µM), 
chloroquine (CQ, IC50=33µM), trichostatin A (TSA, 3µM), hydroxychloroquine (HCQ, 
IC50=57µM), or NSC69603 (IC50=15µM) for either 24 or 48 hours.  Total cellular proteins 
were isolated using boiling lysis buffer (1% SDS, 10mM Tris, pH 7.4).  80µg of whole cell 
extract proteins were resolved on a 10% acrylamide gel and analyzed by Western blot.  
Signals were quantitated by FluoroChem (Alpha Innotech, San Leandro, CA) spot 
densitometry using automatic background subtraction after normalization to β-catenin 
levels.  Data shown represents the mean of three experiments ±SEM.  Statistically 
significant differences from the control are indicated (*p<0.05). 
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 Figure 27.  Downregulation of c-myc protein in MCF-7 cells treated with quinoline 
compounds.  MCF-7 (2x106 cells/60 mm2 dish) were treated with quinidine (QD, 90µM), 
chloroquine (CQ, IC50=33µM), trichostatin A (TSA, 3µM), hydroxychloroquine (HCQ, 
IC50=57µM), or NSC69603 (IC50=15µM) for either 24 or 48 hours.  Total cellular proteins 
were isolated using boiling lysis buffer (1% SDS, 10mM Tris, pH 7.4).  80µg of whole cell 
extract proteins were resolved on a 10% acrylamide gel and analyzed by Western blot.  
Signals were quantitated by FluoroChem (Alpha Innotech, San Leandro, CA) spot 
densitometry using automatic background subtraction after normalization to β-catenin 
levels.  Data shown represents the mean of three experiments ±SEM.  Statistically 
significant differences from the control are indicated (*p<0.05). 
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4.2  Liu, C., Strobl, J.S., Bane, S., Schilling, J.K., McCracken, M., Chatterjee, S.K., Rahim-
Bata, R., Kingston, D.G.I.  (2003) Design, synthesis, and bioactivities of steroid-linked 
taxol analogues as potential targeted drugs for prostate and breast cancer.  Journal of 
Natural Products 
 
The rationale for these studies was to target taxol to estrogen receptor positive (ER+) breast 
cancer by means of selected steroid hormone conjugates.  Cytotoxicity of the synthesized 
estradiol-taxol conjugates was determined in MCF-7 (ERα+,β+) and MDA-MB-231 (ERα-, 
β+) cells using the MTS metabolism assay to generate IC50 values.  In Table 6, the IC50 
values attained for the estradiol-taxol conjugates 9, 11, 14, 16, and 21 compared with the 
IC50 value of taxol in both the MCF-7 and MDA-MB-231 cells are circled in red.  The 
results suggest that the IC50 value for taxol is similar for both cell lines.  Neither compound 
9 nor 11 showed significant selectivity for the ERα+ MCF-7 cell line, while compounds 14 
and 16 showed modest selectivity towards it.  More importantly, compound 21, which is a 
10-substituted derivative, showed significant selectivity towards the ERα+ MCF-7 
compared with the ERα- MDA-MB-231 breast cancer cells.  These results are directing 
future efforts to targeting taxol to ERα+ breast cancer cells by synthesizing estradiol-taxol 
















Table 6.  Cytotoxicity of steroid-linked taxol derivatives. MCF-7 and MDA-MB-231 
breast cancer cells were plated at 4.0x103 and 5.0x102 cells per well in 96-well plates, 
respectively. MTS IC50 growth inhibitory concentrations represent the inhibition of 
mitochondrial metabolism of MTS following a 48 hour exposure to each compound.  
Data are the mean of n=3 independent experiments performed with 10 concentrations of 






IV.  DISCUSSION 
 
Despite improvements in therapeutic treatments for breast cancer within the last thirty 
years, both the absolute cause and the means for its cure still remain elusive.  Although there 
have been advancements in the area of drug development, there is still a lack of effective 
chemotherapeutic agents that are active against breast cancer and that do not display harmful 
toxicity at higher doses or to neighboring normal breast cells and tissues.  Novel strategies 
must be devised to administer potent therapy against cancer cells without the side effects of 
high-dose chemotherapy in breast cancer treatment.  The aim of these studies was to develop 
new drugs which are active against breast cancer by restoring a less malignant 
(differentiated) phenotype, thereby reducing the tumors’ aggressiveness and ultimately 
resulting in death of the human breast tumor cells.  Preliminary studies indicate that two 
quinoline antimalarials, chloroquine and hydroxychloroquine, inhibit proliferation and 
induce differentiation in breast cancer cell lines without toxicity to normal MCF-10A breast 
cells.  Since combination drug therapy is the key to success in the prevention and treatment 
of breast cancer, this proposal seeks to derive better chemotherapeutic agents by using these 
quinolines in combination with the most effective differentiating agents.  Hence the goal of 
these studies was to explore whether a drug combination modulating epigenetic events 
would sensitize breast cancer cells to the antitumor activity of either chloroquine or 
hydroxychloroquine.     
The advantage of using quinolines for breast cancer treatment is that they are already in 
wide use, as antimalarials and anti-inflammatory agents, and their human pharmacology is 
well known.  At lower concentrations, these drugs are not only efficacious, but they are also 
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orally active, inexpensive, and display very low and predictable toxicities in humans.  
Combining these quinolines with effective differentiating agents should ultimately help to 
lower the threshold for chemotherapy-induced cell death in breast cancer.  Differentiation-
inducing agents, such as retinoids, have strong implications in the treatment of acute 
promyelocytic leukemia and have become promising agents for differentiation therapy of 
breast cancer (Baj et al., 2000; Singh et al., 2000).  Retinoids have already been shown to 
play a myriad of potential roles in the prevention and treatment of breast cancer cells, 
including growth inhibition, cell differentiation, and induction of apoptosis.  Several 
retinoids, including ATRA, have been shown to have potent activity in the treatment of 
breast cancer and are now in clinical trials in combination with other cytotoxic agents and 
anti-estrogens (Yang et al., 1999).  Clinically, retinoids have been shown to reverse 
premalignant lesions and inhibit the generation of second primary tumors in some patients 
(Yang et al., 2002).  Concurrently, my data showed that ATRA in combination with 
hydroxychloroquine had the most significant inhibitory effect on tumor cell clonogenic 
survival in both ER+ and ER- breast cancer cells compared to either of the drugs alone 
(Figure 9 and Table 2), showing a 92% and 82% reduction compared to control cells in 
MDA-MB-231 and MCF-7 cells, respectively.  Since clonogenic survival is the most 
sensitive test for predicting the responsiveness of a tumor to clinical treatment, this is a 
promising finding, suggesting a potential role for the combination of hydroxychloroquine 
and ATRA for breast cancer therapy.     
Combination of ATRA with either chloroquine or hydroxychloroquine also enhanced 
the differentiation response.  Lipid droplet accumulation and Ki67 index were elevated in 
both the MCF-7 and MDA-MB-231 breast cancer cell lines (Figures 10 and 11).  Although 
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the antitumor quinolines alone displayed an enhanced Ki67 index, pretreatment with ATRA 
lowered the concentration of chloroquine or hydroxychloroquine needed to achieve the same 
response.  Cell cycle regulatory proteins, E2F-1 and c-myc were both downregulated, 
suggesting that cellular differentiation and cell cycle progression are interdependent.   
Studies have shown that combinations of chemotherapy drugs are the most efficacious, 
by offering distinct ways of destroying the cancer cells; thereby, reducing the chance of the 
cancer becoming resistant to one drug.  A better understanding of factors and mechanisms 
regulating differentiation would reveal new possibilities for successful chemotherapeutic 
approaches.  Both chloroquine and hydroxychloroquine display anti-inflammatory properties 
in epithelial cell lines by regulating the NF-κB family of transcription factors, well-known 
for mediating immune and inflammatory responses.  NF-κB has recently been identified as a 
molecular link between chronic inflammation and cancer.  Recent studies conducted using 
distinct models of inflammation-associated cancer, now show the importance of NF-κB in 
promoting cancer progression during inflammation (Greten et al., 2004; Luo et al., 2004; 
Pikarsky et al., 2004). Results from these studies suggest that NF-κB exerts its oncogenic 
effects by promoting the survival of premalignant epithelial cells while also stimulating 
release of pro-inflammatory mediators from activated macrophages that promote tumor cell 
growth.  The antirheumatic and antitumor properties of chloroquine and hydroxychloroquine 
may be interconnected by a distinct target.  Significant observations link cancer prevention 
and treatment with a common drug target, an enzyme called histone deacetylase (HDAC).  
This HDAC enzyme modifies chromatin structure by removing acetyl groups from lysine 
residues in histones.  The acetylation status of histones is critical for the modulation of 
chromatin structure and the regulation of gene transcription.  When HDAC deacetylates 
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histones at lysine sites, it generates a more condensed chromatin structure, which is 
characterized by transcriptional inactivity or tumor progression.  On the other hand, when 
this HDAC enzyme is inhibited, it results in growth arrest, reverts cells to a differentiated 
phenotype, and leads to death of the human breast tumor cells. 
Since previous work showed that another differentiation-inducing quinoline, quinidine, 
caused down-regulation of HDAC1 protein levels and hyperacetylation of histone H4 in a 
panel of human breast tumor cell lines (Zhou et al., 2000), we wanted to first see if any of 
these factors were responsible for the antiproliferative and differentiation responses 
displayed by the quinolines, chloroquine or hydroxychloroquine in combination with 
ATRA.  In MCF-7 cells, HDAC protein levels had already declined as early as 0.5 h after 
quinoline addition and these levels were further decreased with pretreatment with ATRA 
(Figure 18).  Although a transient response, hyperacetylated histone H3 and histone H4 
protein levels were maximal by 8 h.  Cells pretreated with ATRA before quinoline addition, 
showed the greatest induction of RARβ2 protein levels.  Because these responses are typical 
of known HDAC inhibitory drugs, we tested HDAC enzymatic activity.  To our surprise, 
1µM ATRA alone was identified as a direct HDAC inhibitor (Figure 19).  Direct inhibition 
of HDAC activity by ATRA was sustained, but not decreased further upon combination 
treatment with either chloroquine or hydroxychloroquine; therefore, HDAC inhibition might 
contribute to both MCF-7 and MDA-MB-231 cell differentiation in response to ATRA, but 
not to the differentiation quinolines.   
MS peptide sequence data provide a working-model that supports a role for 
hydroxychloroquine in the regulation of acetylation since both histone H3 and histone H4 
lysine sites were modified in the direction of acetylation, but not all lysine sites were 
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acetylated because histone deacetylase (HDAC) was not completely inhibited by 
hydroxychloroquine alone (Figure 21).  Consistent with the MS model, hydroxychloroquine 
did in fact activate histone acetyltransferase (HAT) enzyme (Figure 22).  Interestingly, 
ATRA was also identified as a direct HAT activator, suggesting a possible interdependent 
role shared by the two agents.  However, ATRA also acts via an independent mechanism by 
inhibiting HDAC enzymatic activity, thus enhancing sensitization of breast cancer cells to 
the antitumor activity of quinolines.   
The goal of these studies was to explore whether a drug combination modulating 
epigenetic events would sensitize breast cancer cells to the antitumor activity of either 
chloroquine or hydroxychloroquine.  The demethylating cytosine analog, 5-Aza-2’-
deoxycytidine (5-Aza-dC) was tested but was not as successful as ATRA in decreasing 
tumor cell clonogenic survival of ER-positive human breast carcinoma cells.  Pretreatment 
of ER-negative breast cancer cells with 5-Aza-dC enhanced the antitumor activity of the 
quinolines similarly to the response from ATRA.  In summary, combination drug therapy 
with differentiation-inducing agents enhance the antiproliferative, differentiation, and 
histone acetylation responses, and thereby, provide a more effective and less toxic 
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